書籍詳細

Part 1 /β遮断薬のプロファイル

P.32 掲載の参考文献

• 1) Ahlquist RP:A study of the adrenotropic receptors. Am J Physiol 153:586-600, 1948
  pubmed

• 2) Cruickshank JM, Prichard BNC:Historical. In:Beta-blockers in Clinical Practice. Churchill Livingstone, Edinburgh, 1988, pp.1-8

• 3) Powell CE, Slater IH:Blocking of inbitory adrenergic receptors by a dichloro analog of isoproterenol. J Pharmacol Exp Ther 122:480-488, 1958

• 4) Black JW, Stephenson JS:Pharmacology of a new beta-adrenergic compound. Lancet i:311-314, 1962
  pubmed

• 5) Gross TP, Wise RP, Knapp DE:Antihypertensive drug use. Trends in the United States from 1973 to 1985. Hypertension 13 (suppl I):S113-S 118, 1989

• 6) BHAT Research Group:A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247:1707-1714, 1982

• 7) Aellig WH:Pindolol-A β-adrenoceptor blocking drugs with partial agonist activity:clinical pharmacological considerations. Br J Clin Pharmacol 13 (suppl 2):S187-S189, 1982

• 8) Lands AM, Arnold A, McAuliff JP et al:Differentiation of receptor systems activated by sympathomimetic amines. Nature 214:597-598, 1967
  pubmed

• 9) Wilhelmsen L, Berglund G, Elmfeldt D et al:the Heart Attack Primary Prevention Study in Hypertension. Hypertension 5:561-572, 1987

• 10) Wikstrand J, Warnold I, Olssen G et al:Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 259:1976-1982, 1988

• 11) UKPDS Group:Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39. BMJ 317:713-720, 1998
  Medical*Online
  pubmed

• 12) Dahlof B, Devereux RB, Kjeldsen S et al:LIFE study group:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomized trial against atenolol. Lancet 359:995-1003, 2002

• 13) Lindholm LH, Ibsen H, Dahlof B et al:LIFE study group:Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE):a randomized trial against atenolol. Lancet 359:1004-1010, 2002

• 14) Staessen JA, Wang J-G, Birkenhager WH:Outcome beyond blood pressure control? Eur Heart J 24:504-514, 2003
  pubmed

• 15) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic beta-adrenergic blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036, 1975
  pubmed

• 16) The Beta-Blocker Evaluation of Survival Trial Investigators:a trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344:1659-1667, 2001

• 17) Fogari R, Zoppi A, Corradi L et al:β-Blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 33:534-539, 1999

• 18) Hennersdorf MG, Perings C, Vester EG:Hemodynamic effects of celiprolol in patients with ischemic and non-ischemic cardiac myopathy. Int J Cardiol 68:289-295, 1999

• 19) Withitz S, Cohen-Solal A, Dartois N et al:CELICARD Group:Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonis t vasodilatory properties. Am J Cardiol 85:1467-1471, 2000

• 20) Manoury P:Betaxolol:chemistry and biological profile in relation to its physico-chemical properties. In:Betaxolol and Other β1-adrenoceptorantagonists. eds by Morselli PL, Kilborn JR, Cavero I et al. L・E・R・S・ Monograph Series Vol 1, Raven Press, New York, 1983, pp.13-19

• 21) McAreavey D, Vermeulen R, Robertson JIS:Newer beta blockers and the treatment of hypertension. Cardiovasc Drugs Ther 5:577-588, 1991

• 22) Palazzuoli A, Calabria P, Versuri MS et al:Carvedilol:something else than a simple beta-blocker? Eur Rev Med Pharmacol Sci 6:115-126, 2002

• 23) Australia/New Zealand Heart Failure Research Collaborative Group:Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 92:212-218, 1995

• 24) Cruickshank JM, Prichard BNC:Profiles of some newer beta-blockers and beta-receptor stabilizers. In:Beta-Blockers in Clinical Practice. Churchill Livingstone, Edinburgh, 1988, pp.925-981

• 25) Guidelines Committee:2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053, 2003

• 26) Chobanian AV, Bakris HR, Black HR et al:the National High Blood Pressure Education Program Coordinating Committee:The seventh report of the Joint National Committee on Prevention, Detection, Treatment of High Blood 289:2560-2572, 2003

• 27) Gibbons RJ, Chatterjee K, Daley J et al:ACC/AHA/ACP-ASIM Guidelines for the Management of Patients with Chronic Stable Angina. J Am Coll Cardiol 33:2092-2197, 1999
  pubmed

• 28) Soriano JB, Hoes AW, Meems L et al:Increased survival with β-blockers:Importance of acillary properties. Prog Cardiovasc Dis 39:445-456, 1997

• 29) Lacat P, Packer M, Chalon S et al:Clinical effect of β-adrenergic blockade in chronic heart failure. A meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 98:1184-1191, 1998

• 30) The Xamotelol in Severe Heart Failure Study:Xamotelol in severe heart failure. Lancet 336:1-6, 1990
  pubmed

P.38 掲載の参考文献

• 1) Prichard BNC:β-adrenergic receptor blockade in hypertension, past, present and future. Br J Clin Pharmacol 5:379-399, 1978

P.44 掲載の参考文献

• 1) Gilman AG, Rall TW, Nies AS et al:Goodman and Gilman's The Pharmacological Basis Of Therapeutics. Pergamon Press, 1990

• 2) 水島裕, 宮本昭正:今日の治療薬'99. 南江堂, 東京, 1999

• 3) 戸田昇, 我孫子保:循環系治療薬の作用メカニズム. 南江堂, 東京, 1998

• 4) Johnsson G, Regardh CG:Clinical pharmacokinetics of β-adrenoceptor blocking drugs. Clin Pharmacokinet 1:233-263, 1976

• 5) van Zwieten PA:Different properties of β-adrenoceptor blockers:characteristics of bopindolol. In:The Position Of Bopindolol, a New β-Blocker' Proceedings, Round Table Conference, Amsterdam, May 23, 1986. ed by van Zwieten PA. Royal Society of Medicine Services, London, New York, 1987, pp.1-11

• 6) Feuerstein G, Yue TL, Ruffolo RR Jr et al:Carvedilol Update:a multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Drugs Today 29:401-419, 1993

• 7) Dunn CJ, Lea AP, Wagstaff AJ et al:Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 54:161-185, 1997
  pubmed

P.51 掲載の参考文献

• 1) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036, 1975
  pubmed

• 2) Gillman MW, Kannel WB, Belanger A et al:Influence of heart rate on mortality among persons with hypertension:the Framingham Study. Am Heart J 125:1148-1154, 1993
  pubmed

• 3) Palatini P, Casiglia E, Julius S et al:High heart rate:a risk factor for cardiovascular death in elderly men. Arch Intern Med 159:585-592, 1999
  pubmed

• 4) Waagstein F, Bristow MR, Swedberg K et al:Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group:beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342:1441-1446, 1993

• 5) Bristow MR, Gilbert EM, Abraham K et al:MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94:2807-2816, 1996

• 6) CIBIS-II Investigators and Committee:The Cardiac Insufficiency Bisoprolol Study (CIBIS-II):a randomized trial. Lancet 353:9-13, 1999

• 7) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999

• 8) Packer M, Coats AJ, Fowler MB et al:Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001
  pubmed

• 9) The CAPRICORN Investigators:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomized trial. Lancet 357:1385-1390, 2001
  pubmed

• 10) Handa S, Hosoda S, Sasayama S et al:MUCHA Investigators. Multicenter carvedilol heart failure assessment (MUCHA) trial. J Card Fail 6 (suppl 3):S81, 2000

• 11) The TIMI Study Group:Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction:results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. N Engl J Med 320:618-627, 1991

• 12) Hennekens CH:Clinical Trials in Cardiovascular Disease:a Companion to Braunwald's Heart Disease. Philadelphia, WB Saunders, 1999, p.84

• 13) Wikstrand J, Warnold I, Tuomilehto J et al:Metprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study. Hypertension 17:579-588, 1991

P.55 掲載の参考文献

• 1) Prichard BN, Gillam PMS:Use of propranolol in the treatment of hypertension. Br Med J 2:725-727, 1964

• 2) Wilkstrand J, Warnord I, Olsson G et al:Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 259:1976-1982, 1988

• 3) Chobanian AV, Bakris GL, Black HR et al:The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:the JNC 7 report. JAMA 289:2560-2572, 2003
  pubmed

• 4) Guidelines Committee:2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053, 2003

Part 2/ β遮断薬の臓器別作用

P.63 掲載の参考文献

• 1) Kim M, Kukin M:New advances in the pharmacological management of chronic heart failure. Expert Opin Pharmacother 1:261-269, 2000
  pubmed

• 2) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036, 1975
  pubmed

• 3) Cohn JN, Levine TB, Olivari MT et al:Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819-823, 1984
  pubmed

• 4) Rockman HA, Koch WJ, Lefkowitz RJ:Seven-transmembrane-spanning receptors and heart function. Nature 415:206-212, 2002
  pubmed

• 5) Port JD, Bristow MR:Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol 33:887-905, 2001
  pubmed

• 6) Swynghedauw B:Molecular mechanisms of myocardial remodeling. Physiol Rev 79:215-262, 1999
  pubmed

• 7) Yamazaki T, Komuro I, Zou Y et al:Protein kinase A and protein kinase C synergistically activate the Raf-1 kinase/mitogen-activated protein kinase cascade in neonatal rat cardiomyocytes. J Mol Cell Cardiol 29:2491-2501, 1997
  pubmed

• 8) Zou Y, Komuro I, Yamazaki T et al:Both Gs and Gi proteins are critically involved in isoproterenol-induced cardiomyocyte hypertrophy. J Biol Chem 274:9760-9770, 1999
  pubmed

• 9) Yamazaki T, Komuro I, Zou Y et al:Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both alpha 1-and beta-adrenoceptors. Circulation 95:1260-1268, 1997
  pubmed

• 10) Grimm D, Huber M, Jabusch HC et al:Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload:effects of beta-receptor blockade. J Mol Cell Cardiol 33:487-501, 2001
  pubmed

• 11) Senzaki H, Paolocci N, Gluzband YA et al:beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II I combined with evolving cardiac dysfunction. Circ Res 86:807-815, 2000
  pubmed

• 12) Saito S, Hiroi Y, Zou Y et al:beta-Adrenergic pathway induces apoptosis through calcineurin activation in cardiac myocytes. J Biol Chem 275:34528-34533, 2000
  pubmed

• 13) Singh K, Xiao L, Remondino A et al:Adrenergic regulation of cardiac myocyte apoptosis. J Cell Physiol 189:257-265, 2001
  pubmed

• 14) Adams JW, Brown JH:G-proteins in growth and apoptosis:lessons from the heart. Oncogene 20:1626-1634, 2001
  pubmed

• 15) Sabbah HN, Sharov VG, Gupta RC et al:Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. J Am Coll Cardiol 36:1698-1705, 2000
  pubmed

• 16) Sawyer DB, Colucci WS:Mitochondrial oxidative stress in heart failure:"oxygen wastage" revisited. Circ Res 86:119-120, 2000
  pubmed

• 17) Nakamura K, Kusano K, Nakamura Y et al:Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 105:2867-2871, 2002
  pubmed

• 18) Doi M, Yano M, Kobayashi S et al:Propranolol prevents the development of heart failure by restoring FKBP 12.6-mediated stabilization of ryanodine receptor. Circulation 105:1374-1379, 2002

• 19) Reiken S, Gaburjakova M, Gaburjakova J et al:beta-adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure. Circulation 104:2843-2848, 2001
  pubmed

• 20) Katz AM:A growth of ideas:role of calcium as activator of cardiac contraction. Cardiovasc Res 52:8-13, 2001.
  pubmed

• 21) Marks AR, Marx SO, Reiken S:Regulation of ryanodine receptors via macromolecular complexes:a novel role for leucine/isoleucine zippers. Trends Cardiovasc Med 12:166-170, 2002
  pubmed

• 22) Luo W, Grupp IL, Harrer J et al:Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 75:401-409, 1994
  pubmed

• 23) Engelhardt S, Hein L, Wiesmann F et al:Progressive hypertrophy and heart failure in beta 1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96:7059-7064, 1999
  pubmed

• 24) Milano CA, Allen LF, Rockman HA et al:Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science 264:582-586, 1994
  pubmed

• 25) Rohrer DK:Physiological consequences of beta-adrenergic receptor disruption. J Mol Med 76:764-772, 1998
  pubmed

• 26) Bristow MR:Why does the myocardium fail? Insights from basic science. Lancet 352 (suppl 1):SI 8-SI 14, 1998

P.73 掲載の参考文献

• 1) Guimaraes S, Moura D:Vascular adrenoceptors:an update. Pharmacol Rev 53:319-356, 2001
  pubmed

• 2) Vanhoutte PM:Endothelial adrenoceptors. J Cardiovasc Pharmacol 38:796-808, 2001
  pubmed

• 3) Ritter JM. Nebivolol:endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol 38 (suppl 3):S 13-S 16, 2001

• 4) Kalinowski L, Dobrucki LW, Szczepanska-Konkel M et al:Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux:a novel mechanism for antihypertensive action. Circulation 107:2747-2752, 2003
  pubmed

• 5) Intengan HD, Schiffrin EL:Disparate effects of carvedilol versus metoprolol treatment of stroke-prone spontaneously hypertensive rats on endothelial function of resistance arteries. J Cardiovasc Pharmacol 35:763-768, 2000
  pubmed

• 6) Cockcroft JR, Chowienczyk PJ, Brett SE et al:Nebivolol vasodilates human forearm vasculature:evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 274:1067-1071, 1995

• 7) Tzemos N, Lim PO, MacDonald TM:Nebivolol reverses endothelial dysfunction in essential hypertension:a randomized, double-blind, crossover study. Circulation 104:511-514, 2001
  pubmed

• 8) Adler B, Gimbrone MA Jr, Schafer AI et al:Prostacyclin and beta-adrenergic catecholamines inhibit arachidonate release and PGI2 synthesis by vascular endothelium. Blood 58:514-517, 1981
  pubmed

• 9) Beckmann ML, Gerber JG, Byyny RL et al:Propranolol increases prostacyclin synthesis in patients with essential hypertension. Hypertension 12:582-588, 1988
  pubmed

• 10) Garlichs CD, Zhang H, Mugge A et al:Beta-blockers reduce the release and synthesis of endothelin-1 in human endothelial cells. Eur J Clin Invest 29:12-16, 1999
  pubmed

• 11) Ohlstein EH, Arleth AJ, Storer B et al:Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells. J Mol Cell Cardiol 30:167-173, 1998
  pubmed

• 12) Krum H, Gu A, Wilshire-Clement M et al:Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am Heart J 131:337-341, 1996
  pubmed

• 13) Bessho H, Suzuki J, Tobe A:Vascular effects of betaxolol, a cardioselective beta-adrenoceptor antagonist, in isolated rat arteries. Jpn J Pharmacol 55:351-358, 1991
  pubmed

• 14) Satoh N, Suzuki J, Bessho H et al:Effects of betaxolol on cardiohemodynamics and coronary circulation in anesthetized dogs:comparison with atenolol and propranolol. Jpn J Pharmacol 54:113-119, 1990
  pubmed

• 15) Adachi T, Hori S, Miyazaki K et al:Rapid increase in plasma nitrite concentration following intravenous administration of nipradilol. Eur J Pharmacol 286:201-204, 1995
  pubmed

• 16) Jayachandran M, Hayashi T, Sumi D et al:Up-regulation of endothelial nitric oxide synthase through beta (2)-adrenergic receptor--the role of a beta-blocker with NO-releasing action. Biochem Biophys Res Commun 280:589-594, 2001
  pubmed

• 17) Thakur NK, Hayashi T, Sumi D et al:Antiatherosclerotic effect of beta-blocker with nitric oxide-releasing action on the severe atherosclerosis. J Cardiovasc Pharmacol 39:298-309, 2002
  pubmed

• 18) Yasunari K, Maeda K, Nakamura M et al:Carvedilol inhibits pressure-induced increase in oxidative stress in coronary smooth muscle cells. Hypertens Res 25:419-425, 2002
  pubmed

• 19) Lopez BL, Christopher TA, Yue TL et al:Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. Pharmacology 51:165-173, 1995
  pubmed

• 20) Janssen PM, Zeitz O, Rahman A et al:Protective role of nebivolol in hydroxyl radical induced injury. J Cardiovasc Pharmacol 38 (suppl 3):S17-S 23, 2001

• 21) Maggi E, Marchesi E, Covini D et al:Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 27:532-538, 1996
  pubmed

• 22) Yue TL, Wang X, Gu JL et al:Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyte adhesion to endothelial cells by inhibition of LDL oxidation. Eur J Pharmacol 294:585-591, 1995
  pubmed

• 23) Matsuda Y, Akita H, Terashima M et al:Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am Heart J 140:753-759, 2000
  pubmed

• 24) Giugliano D, Acampora R, Marfella R et al:Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern 126:955-959, 1997
  pubmed

• 25) Fogari R, Zoppi A, Tettamanti F et al:Beta-blocker effects on plasma lipids in antihypertensive therapy:importance of the duration of treatment and the lipid status before treatment. J Cardiovasc Pharmacol 16 (suppl 5):S76-S 80, 1990

• 26) Ohlstein EH, Douglas SA, Sung CP et al:Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA 90:6189-6193, 1993
  pubmed

• 27) Brehm BR, Wolf SC, Bertsch D et al:Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res 49:430-439, 2001
  pubmed

• 28) Rossig L, Haendeler J, Mallat Z et al:Congestive heart failure induces endothelial cell apoptosis:protective role of carvedilol. J Am Coll Cardiol 36:2081-2089, 2000
  pubmed

• 29) Ohlstein EH, Vickery L, Arleth A et al:Carvedilol, a novel cardiovascular agent, inhibits development of vascular and ventricular hypertrophy in spontaneously hypertensive rats. Clin Exp Hypertens 16:163-177, 1994
  pubmed

• 30) Whittington-Coleman PJ, Carrier O Jr, Douglas BH:The effects of propranolol on cholesterol-induced atheromatous lesions. Atherosclerosis 18:337-345, 1973
  pubmed

• 31) Hurt E, Camejo G:Effect of arterial proteoglycans on the interaction of LDL with human monocyte-derived macrophages. Atherosclerosis 67:115-126, 1987
  pubmed

• 32) Linden T, Camejo G, Wiklund O et al:Effect of short-term beta blockade on serum lipid levels and on the interaction of LDL with human arterial proteoglycans. J Clin Pharmacol 30 (suppl 2):S124-S 131, 1990

• 33) Feuerstein GZ, Fisher M, Nunnart J et al:Carvedilol inhibits aortic lipid deposition in the hypercholesterolemic rat. Pharmacology 54:24-32, 1997
  pubmed

• 34) Wikstrand J, Berglund G, Hedblad B et al:Antiatherosclerotic effects of beta-blockers. Am J Cardiol 91 (suppl H):S25-S 29, 2003

P.79 掲載の参考文献

• 1) 北川一夫, 松本昌泰, 堀正二:β遮断薬の脳循環に対する作用.β遮断薬のすべて.荻原俊男, 築山久一郎, 横山光宏編, 先端医学社, 東京, 2000, pp.75-79

• 2) SHEP Cooperative Research Group.:Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 265:3255-3264, 1991

• 3) Hansson L, Lindholm LH, Ekbom T et al:Randomised trial of old and new antihypertensive drugs in elderly patients:cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354:1751-11756, 1999
  pubmed

• 4) Dahlof B, Devereux RB, Kjeldsen SE et al:Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE):a randomized trial against atenolol. Lancet 359:995-1003, 2002
  pubmed

• 5) 松本昌泰, 木村和文, 鎌田武信:脳底部血管の神経薬理学的特性とその病理・病態的意義. 臨床科学27:987-993, 1991

• 6) Madsen PL, Vorstrup S, Schmidt JF et al:Effect of acute and prolonged treatment with propranolol on cerebral blood flow and cerebral oxygen metabolism in healthy volunteers. Eur J Clin Pharmacol 39:295-297, 1990
  pubmed

• 7) Olsen KS, Svendsen LB, Larsen FS et al:Effect of labetalol on cerebral blood flow, oxygen metabolism and autoregulation in healthy humans. Br J Anaesth 75:51-54, 1995
  pubmed

• 8) James IM, Yogendran L, McLaughlin K et al:Blood pressure lowering and cerebral blood flow:a comparison of the effects of carvedilol and propranolol on the cerebral circulation in hypertensive patients. J Cardiovasc Pharmacol 19 (suppl 1):S40-S 43, 1992.

• 9) 黒瀬等:アドレナリン受容体とドーパミン受容体. 蛋白質核酸酵素42:120-130, 1997

• 10) Imura T, Shimohama S, Sato M et al:Differential expression of small heat shock proteins in reactive astrocytes after focal ischemia:possible role of β-adrenergic receptor. J Neurosci 19:9768-9779, 1999

• 11) Amory DW, Grigore A, Amory JK et al:Neuroprotection is associated with β-adrenergic receptor antagonists during cardiac surgery:evidence from 2575 patients. J Cardiothorac Vasc Anesth 16:270-277, 2002

• 12) Heckbert SR, Longstreth WT, Psaty BM et al:The association of antihypertensive agents with MRI white matter findings and with modifies mini-mental state examination in older adults. J Am Geriatr Soc 45:1423-1433, 1997
  pubmed

• 13) Lysko PG, Lysko KA, Yue TL et al:Neuro-protective effects of carvedilol, a new antihypertensive agent, in cultured rat cerebellar neurons and in gerbil global brain ischemia. Stroke 23:1630-1636, 1992

• 14) Saviz SI, Erhardt JA, Anthony JV et al:The novel β-blocker, carvedilol, provides neuro-protection in transient focal stroke. J Cereb Blood Flow Metab 20:1197-1204, 2000

• 15) Madsen PL, Hasselbalch SG, Hagemann LP et al:Persistent resetting of the cerebral oxygen/glucose uptake ration by brain activation:evidence obtained with the Kety-Schmidt technique. J Cereb Blood Flow, Metab 15:485-491, 1995

• 16) Madsen PL, Linde R, Hasselbach SG et al:Activation-induced resetting of cerebral oxygen and glucose uptake in the rat. J Cereb Blood Flow Metab 18:742-748, 1998

• 17) Fillenz M, Lowry JP, Boutelle MG et al:The role of astrocytes and noradrenaline in neuronal glucose metabolism. Acta Physiol Scand 167:275-284, 1999
  pubmed

• 18) Schmalbruch IK, Linde R, Paulson OB et al:Activation-induced resetting of cerebral metabolism and flow is abolished by β-adrenergic blockade with propranolol. Stroke 33:251-255, 2002

P.85 掲載の参考文献

• 1) Beaufils M:Alterations in renal hemodynamics during chronic and acute beta-blockade in humans. Am J Hypertens 2 (part 2):S233-S 236, 1989

• 2) Epstein M, Oster JR:Beta-blockers and renal function:a reappraisal. J Clin Hypertens 1:85-99, 1985
  pubmed

• 3) Epstein M, Oster JR, Hollenberg NK:Beta-blockers and the kidney:implications for renal function and renin release. Physiologist 28:53-63, 1985
  pubmed

• 4) Epstein M, Oster JR:Beta-blockers and the kidney. Miner Electrolyte Metab 8:237-254, 1982
  pubmed

• 5) Wilkinson R:Beta-blockers and renal function. Drugs 23:195-206, 1982
  pubmed

• 6) Textor SC, Fouad FM, Bravo EL et al:Redistribution of cardiac output to the kidneys during oral nadolol administration. N Engl J Med 307:601-605, 1982

• 7) Nakaoka H, Kitahara Y, Amano M et al:Effect of beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension. Hypertension 10:221-225, 1987
  pubmed

• 8) Pettersson K, Anderson J, Sjolander M et al:Atrial natriuretic peptide and the natriuresis due to acute beta-blockade in conscious hypertensive rats. Clin Exp Hypertens A 9:95-107, 1987
  pubmed

• 9) van Baak M, Struyker-Boudier H, Smits J:Antihypertensive mechanisms of beta-adrenoceptor blockade:a review. Clin Exp Hypertens A 7:1-72, 1985
  pubmed

• 10) Struyker-Boudier HA, Vervoort-Peters LH, Rousch MJ et al:Beta-adrenoceptors in kidney tubules of spontaneously hypertensive and normotensive rats. Life Sci 38:137-145, 1986
  pubmed

• 11) Struyker-Boudier HA, Smits JF:Antihypertensive action of beta-adrenoceptor blocking drugs. The role of intrarenal mechanisms. Am J Hypertens 11 (suppl 1):S237-S 240, 1989

• 12) Weber M, Drayer J:Renal effects of beta-adrenoceptor blockade. Kidney Int 18:686-699, 1980
  pubmed

• 13) Cruz F, O'Neill W, Clifton G et al:Effects of labetalol and methyldopa on renal function. Clin Pharmacol Ther 30:57-63, 1981

• 14) Rasmussen S, Nielsen P:Blood pressure, body fluid volumes, and glomerular filtration rate during treatment with labetalol in essential hypertension. Br J Clin Pharmacol 12:249-353, 1981

• 15) Dupont A:Effects of carvedilol on renal function. Eur Clin Pharmacol 38 (suppl 2):S96-S 100, 1990

• 16) Shiigai T:Effects of long-term therapy with arotinolol on blood pressure and renal function in hypertensive patients with chronic renal failure. Clin Ther 15:330-336, 1993
  pubmed

• 17) Suzuki H, Nakamoto H, Nemoto H et al:Control of blood pressure and prevention of end-organ damage in patients with accelerated hypertension by combination with arotinolol and extended release nifedipine. Hypertens Res 23:159-166, 2000
  pubmed

• 18) Siewert-Dell A, Ljungman S, Harford M et al:Effect of 14 years of antihypertensive treatment on renal function and urinary albumin excretion in primary hypertension. Am J Hypertens 9:841-849, 1996

Part 3/ 酸化ストレスとβ遮断薬

P.91 掲載の参考文献

• 1) Hishikawa K, Oemar BS, Yang Z et al:Pulsatile stretch stimulates superoxide production and activates nuclear factor-kappa B in human coronary smooth muscle. Circ Res 81:797-803, 1997
  pubmed

• 2) Yasunari K, Maeda K, Nakamura N et al:Pressure promotes angiotensin II-mediated migration of human coronary smooth muscle cells through increase in oxidative stress. Hypertension 39:433-437, 2002

• 3) Yasunari K, Maeda K, Nakamura N et al:Carvedilol inhibits pressure-induced increase in oxidative stress in coronary smooth muscle cells. Hypertens Res 25:419-425, 2002

• 4) Schmid-Schobein GW, Seiffge D, DeLano FA et al:Leukocyte counts and activation in spontaneously hypertensive and normotensive rats. Hypertension 17:323-330, 1991

• 5) Welch WJ, Mendonca M, Aslam S et al:Roles of oxidative stress and AT1 receptors in renal hemodynamics and oxygenation in the postclipped 2 K, 1 C kidney. Hypertension 41:692-696, 2003

• 6) Ohmori M, Kitoh Y, Harada K et al:Polymorphonuclear leukocytes (PMNS) function in SHR, L-NAME-and DOCA/salt-induced hypertensive rats. J Hypertens 18:703-707, 2000
  pubmed

• 7) Maeda K, Yasunari K, Sato EF et al:Activation of protein kinase C and NADPH oxidase of leukocytes in spontaneously hypertensive rats. Hypertens 26:999-1006, 2003
  pubmed

• 8) Pontremoli S, Salamino F, Sparatore B et al:Enhanced activation of the respiratory burst oxidase in neutrophils from hypertensive patients. Biochem Biophys Commun 158:966-972, 1989
  pubmed

• 9) Higashi Y, Sasaki S, Nakagawa K et al:Endothelial function and oxidative stress in renovascular hypertension. N Eng J Med 346:1954-1962, 2002

• 10) Yasullari K, Maeda K, Nakamura N et al:Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. Hypertension 39:777-780, 2002

• 11) Yasunari K, Maeda K, Nakamura N et al:Carvedilol inhibits oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. Am J Med (in press), 2004

• 12) Packer M, Coats AJ, Fowler MB, et al:Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001
  pubmed

P.98 掲載の参考文献

• 1) Ide T, Tsutsui H, Kinugawa S et al:Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 85:357-363, 1999
  pubmed

• 2) Josephson RA, Silverman HS, Lakatta EG et al:Study of the mechanisms of hydrogen peroxide and hydroxyl free radical-induced cellular injury and calcium overload in cardiac myocytes. J Biol Chem 266:2354-2361, 1991
  pubmed

• 3) Nakamura K, Fushimi K, Kouchi H et al:Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 98:794-799, 1998
  pubmed

• 4) Siwik DA, Tzortzis JD, Pimental DR et al:Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro. Circ Res 85:147-153, 1999
  pubmed

• 5) McMurray J, Chopra M, Abdullah I et al:Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 14:1493-1498, 1993
  pubmed

• 6) Nakamura K, Kusano K, Nakamura Y et al:Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 105:2867-2871, 2002
  pubmed

• 7) Uchida K, Stadtman ER:Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc Natl Acad Sci USA 89:4544-4548, 1992
  pubmed

• 8) Toyokuni S, Miyake N, Hiai H et al:The monoclonal antibody specific for the 4-hydroxy-2-nonenal histidine adduct. FEBS Lett 359:189-191, 1995
  pubmed

• 9) Uchida K:4-hydroxy-2-nonenal:a product and mediator of oxidative stress. Prog Lipid Res 42:318-343, 2003
  pubmed

• 10) Toyokuni S:Reactive oxygen species-induced molecular damage and its application in pathology Pathol Int 49:91-102, 1999
  pubmed

• 11) Eaton P, Li JM, Hearse DJ et al:Formation of 4-hydroxy-2-nonenal-modified proteins in ischemic rat heart. Am J Physiol 276 (3 Pt 2):H935-H943, 1999

• 12) Haenen GR, Plug HJ, Vermeulen NP et al:Contribution of 4-hydroxy-2, 3-transnonenal to the reduction of beta-adrenoceptor function in the heart by oxidative stress. Life Sci 45:71-76, 1989

• 13) Bhatnagar A:Electrophysiological effects of 4-hydroxynonenal, an aldehydic product of lipid peroxidation, on isolated rat ventricular myocytes. Circ Res 76:293-304, 1995
  pubmed

• 14) Ishikawa T, Esterbauer H, Sies H:Role of cardiac glutathione transferase and of the glutathione S-conjugate export system in biotransformation of 4-hydroxynonenal in the heart. J Biol Chem 261:1576-1581, 1986

• 15) Cohn JN, Levine TB, Olivari MT et al:Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819-823, 1984
  pubmed

• 16) Francis GS, Benedict C, Johnstone DE et al:Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82:1724-1729, 1990
  pubmed

• 17) Obata T, Yamanaka Y:Cardiac microdialysis of salicylic acid. OH generation on nonenzymatic oxidation by norepinephrine in rat heart. Biochem Pharmacol 53:1375-1378, 1997
  pubmed

• 18) Singal PK, Beamish RE, Dhalla NS:Potential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease. Adv Exp Med Biol 161:391-401, 1983
  pubmed

• 19) Sawyer DB, Siwik DA, Xiao L et al:Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 34:379-388, 2002
  pubmed

• 20) Xiao L, Pimentel DR, Wang J et al:Role of reactive oxygen species and NAD(P) H oxidase in alpha (1)-adrenoceptor signaling in adult rat cardiac myocytes. Am J Physiol Cell Physiol 282:C926-C 934, 2002

• 21) Remondino A, Kwon SH, Communal C et al:Beta-adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway. Circ Res 92:136-138, 2003
  pubmed

• 22) Kakishita M, Nakamura K, Asanuma M et al:Direct evidence for increased hydroxyl radicals in angiotensin II-induced cardiac hypertrophy through angiotensin II type 1 a receptor. J Cardiovasc Pharmacol-42 (suppl 1):S67-S 70, 2003

• 23) Bendall JK, Cave AC, Heymes C et al:Pivotal role of a gp91 (phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 105:293-296, 2002
  pubmed

• 24) Holzinger C, Schollhammer A, Imhof M et al:Phenotypic patterns of mononuclear cells in dilated cardiomyopathy. Circulation 92:2876-2885, 1995
  pubmed

• 25) Matsumori A, Yamada T, Suzuki H et al:Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 72:561-566, 1994
  pubmed

• 26) Torre-Amione G, Kapadia S, Lee J et al:Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93:704-711, 1996
  pubmed

• 27) Kubota T, McTiernan CF, Frye CS et al:Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 81:627-635, 1997
  pubmed

• 28) Tsutamoto T, Wada A, Matsumoto T et al:Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J Am Coll Cardiol 37:2086-2092, 2001
  pubmed

• 29) Ide T, Tsutsui H, Kinugawa S et al:Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res 86:152-157, 2000
  pubmed

• 30) Pimentel DR, Amin JK, Xiao L et al:Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ Res 89:453-460, 2001
  pubmed

• 31) Treasure CB, Vita JA, Cox DA et al:Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 81:772-779, 1990
  pubmed

• 32) Griendling KK, Sorescu D, Ushio-Fukai M:NAD(P) H oxidase:role in cardiovascular biology and disease. Circ Res 86:494-501, 2000
  pubmed

• 33) Azumi H, Inoue N, Takeshita S et al:Expression of NADH/NADPH oxidase p 22 phox in human coronary arteries. Circulation 100:1494-1498, 1999

• 34) Heymes C, Bendall JK, Ratajczak P et al:Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41:2164-2171, 2003
  pubmed

• 35) Maack C, Kartes T, Kilter H et al:Oxygen free radical release in human failing myocardium is associated with increased activity of rac 1-GTPase and represents a target for statin treatment. Circulation 108:1567-1574, 2003

• 36) Li Y, Huang TT, Carlson EJ et al:Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 11:376-381, 1995
  pubmed

• 37) Lebovitz RM, Zhang H, Vogel H et al:Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci USA 493:9782-9787, 1996

• 38) Hiroi S, Harada H, Nishi H et al:Polymorphisms in the SOD 2 and HLA-DRB 1 genes are associated with nonfamilial idiopathic dilated cardiomyopathy in Japanese. Biochem Biophys Res Commun 261:332-339, 1999

• 39) Lai CC, Peng M, Huang L et al:Chronic exposure of neonatal cardiac myocytes to hydrogen peroxide enhances the expression of catalase. J Mol Cell Cardiol 28:1157-1163, 1996
  pubmed

• 40) Dieterich S, Bieligk U, Beulich K et al:Gene expression of antioxidative enzymes in the human heart:increased expression of catalase in the end-stage failing heart. Circulation 101:33-39, 2000
  pubmed

• 41) Packer M, Bristow MR, Cohn JN et al:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355, 1996
  pubmed

• 42) CIBIS-II Investigators and Committees:The Cardiac Insufficiency Bisoprolol Study II (CIBIS II):a randomised trial. Lancet 353:9-13, 1999

• 43) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999

• 44) Packer M, Coats AJ, Fowler MB et al:Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001
  pubmed

• 45) Kukin ML, Kalman J, Charney RH et al:Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 99:2645-2651, 1999
  pubmed

• 46) Holmer SR, Kaissling B, Putnik K et al:Beta-adrenergic stimulation of renin expression in vivo. J Hypertens 15:1471-1479, 1997
  pubmed

• 47) Fung JW, Yu CM, Yip G et al:Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 92:406-410, 2003

• 48) Barki-Harrington L, Luttrell LM, Rockman HA:Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist:a functional role for receptor-receptor interaction in vivo. Circulation 108:1611-1618, 2003
  pubmed

• 49) Murray DR, Prabhu SD, Chandrasekar B:Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 101:2338-2341, 2000
  pubmed

• 50) Ohtsuka T, Hamada M, Hiasa G et al:Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 37:412-417, 2001
  pubmed

• 51) Ohtsuka T, Hamada M, Saeki H et al:Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 89:996-999, 2002
  pubmed

• 52) Dandona P, Karne R, Ghanim H et al:Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 101:122-124, 2000
  pubmed

• 53) Yue TL, Cheng HY, Lysko PG et al:Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 263:92-98, 1992
  pubmed

• 54) Flesch M, Maack C, Cremers B et al:Effect of beta-blockers on free radical-induced cardiac contractile dysfunction. Circulation 100:346-353, 1999
  pubmed

• 55) Keith ME, Jeejeebhoy KN, Langer A et al:A controlled clinical trial of vitamin E supplementation in patients with congestive heart failure. Am J Clin Nutr 73:219-224, 2001

• 56) Poole-Wilson PA, Swedberg K, Cleland JG et al:Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET):randomised controlled trial. Lancet 362:7-13, 2003

P.107 掲載の参考文献

• 1) Belch JJ, Bridges AB, Scott N et al:Oxygen free radicals and congestive heart failure. Br Heart J 65:245-248, 1991
  pubmed

• 2) McMurray J, Chopra M, Abdullah I et al:Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 14:1493-1498, 1993
  pubmed

• 3) Mallat Z, Philip I, Lebret M et al:Elevated levels of 8-iso-prostaglandin F 2 α in pericardial fluid of patients with heart failure:a potential role for in vivo oxidant stress in ventricular dilatation progression to heart failure. Circulation 97:1536-1539, 1998

• 4) Hill MF, Singal PK:Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Pathol 148:291-300, 1996
  pubmed

• 5) Ide T, Tsutsui H, Kinugawa S et al:Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res 86:152-157, 2000
  pubmed

• 6) Ide T, Tsutsui H, Kinugawa S et al:Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 85:357-363, 1999
  pubmed

• 7) Ide T, Tsutsui II, Hayashidani S et al:Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts following myocardial infarction. Circ Res 88:529-535, 2001

• 8) Suematsu N, Tsutsui H, Wen J et al:Oxidative stress mediates tumor necrosis factor-(induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 107:1418-1423, 2003
  pubmed

• 9) Tsutsui H, Ide T, Shiomi T et al:8-oxo-dGTPase, which prevents oxidative stress-induced DNA damage, increases in the mitochondria from failing hearts. Circulation 104:2883-2885, 2001
  pubmed

• 10) Siwik DA, Tzortzis JD, Pimental DR et al:Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro. Circ Res 85:147-153, 1999
  pubmed

• 11) Tsutsui H, Ide T, Kinugawa S et al:Greater susceptibility of failing cardiac myocytes to oxygen free radical-mediated injury. Cardiovasc Res 49:103-109, 2001

• 12) Kinugawa S, Tsutsui H, Ide T et al:Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice. Role of oxidative stress. Circ Res 87:392-398, 2000
  pubmed

• 13) Hayashidani S, Tsutsui H, Ikeuchi M et al:Targeted deletion of MMP-2 attenuates early left ventricular rupture and late remodeling after experimental myocardial infarction Am J Physiol Heart Circ Physiol 285:H1229-H1235, 2003
  pubmed

• 14) Tsutsui H, Ide T, Hayashidani S et al:Enhanced generation of reactive oxygen species in the limb skeletal muscles from a murine infarct model of heart failure. Circulation 104:134-136, 2001
  pubmed

• 15) Flesch M, Maack C, Cremers B et al:Effects of beta-blockers on free-radical-induced cardiac contractile dysfunction. Circulation 100:346-353, 1999
  pubmed

• 16) Tsutsui H, Ide T, Kinugawa S et al:Protective effects of carvedilol against oxygen radical mediated cardiac myocyte injury. J Cardiovasc Pharmacol 34 (suppl 1):S73-S 76, 1999

• 17) Yue TL, Ma XL, Wang X et al:Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res 82:166-174, 1998
  pubmed

• 18) Poole-Wilson PA, Swedberg K, Cleland JG et al:Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET):randomised controlled trial. Lancet 362:7-13, 2003

Part 4/ 高血圧

P.118 掲載の参考文献

• 1) Chobanian AV, Bakris HR, Black HR et al:the National High Blood Pressure Education Program Coordinating Committee:The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289:2560-2572, 2003

• 2) Guidelines Committee:2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053, 2003

• 3) McAlister FA, Zarnke KB, Campbell NR et al:Canadian Hypertension Recommendations Working Group:The 2001 Canadian recommendations for the management of hypertension:part two-therapy. Can J Cardiol 18:625-641, 2002

• 4) Hunt SA, Baker DW, Chin MH et al:ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult:excutive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 104:2996-3007, 2001

• 5) American Diabetes Association:Treatment of hypertension in adults with diabetes. Diabetes Care 26 (suppl 1):S80-S 82, 2003

• 6) Frishman WH:Cardiology patient page:Beta-adrenergic blockers. Circulation 107:e117, 2003
  pubmed

• 7) Hanes DS, Weir MR:The β blockers:Are they as protective in hypertension as in other cardiovascular conditions? J Clin Hypertens 3:236-243, 2001

• 8) Klein L, O'Connor CM, Gattis WA et al:Pharmacologic therapy for patients with chronic heart failure and reduced systolic function:review of trials and practical considerations. Am J Cardiol 91 (suppl 9 A):S18-S40, 2003

• 9) Dahlof B, Devereux RB, Kjeldsen SE et al:LIFE study group:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomized trial against atenolol. Lancet 359:995-1003, 2002

• 10) Lindholm LH, Ibsen H, Dahlof B et al:LIFE study group:Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE):a randomized trial against atenolol. Lancet 359:1004-1010, 2002

• 11) Staessen JA, Wang J-G, Birkenhager WH:Outcome beyond blood pressure control? Eur Heart J 24:504-514, 2003
  pubmed

• 12) Devereux RB, Dahlof B, Kjeldsen SE et al:LIFE randomized trial. Ann Intern Med 139:169-177, 2003
  pubmed

• 13) Docherty A, Dunn FG:Treatment of hypertensive patients with coexisting coronary arterial disease. Curr Opin Cardiol 18:268-271, 2003
  pubmed

• 14) Heidland UE, Strauer BE:Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 104:1477-1482, 2001
  pubmed

• 15) Gibbons RJ, Chatterjee K, Daley J, Douglas JS, et al:ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina). J Am Coll Cardiol 33:2092-2197, 1999

• 16) Smith SC Jr, Blair SN, Bonow RO et al:AHA/ACC Guidelines for preventing heart attack and death in patients with aterosclerotic cardiovascular disease:2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 104:1577-1579, 2001

• 17) Jonas M, Reicher-Reiss H, Boyko V et al:Bezafibrate Infarction Prevention (BIP) Study Group:Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Cardiol 77:1273-1277, 1996

• 18) Haim M, Shotan A, Boyko V et al:The Bezafibrate Infarction Prevention (BIP) Study Group:Effect of beta-blocker therapy in patients with coronary artery disease in New York Heart Association Classes II and III. Am J Cardiol 81:1455-1460, 1998

• 19) von Arnim T:TIBBS Investigators:Prognostic significance of transient ischemic episodes:response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBS) follow-up. J Am Coll Cardiol 28:20-24, 1996

• 20) Heidenreich PA, McDonald KM, Hastie T et al:Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 281:1927-1936, 1999
  pubmed

• 21) Gottlieb SS, McCarter RJ, Vogel RA:Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339:489-497, 1998
  pubmed

• 22) Dei Cas L, Metra M, Nodari S, Dei Cas A et al:Prevention and management of chronic heart failure at risk. Am J Cardiol 91 (9 A):S10-S17, 2003

• 23) Psaty BM, Smith NL, Siscovick DS et al:Health outcomes associated with antihypertensive therapies used as first-line agents. A systemic review and meta-analysis. JAMA 277:739-745, 1997

• 24) Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology:Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22:1527-1560, 2001

• 25) Herlitz J, Wikstrand J, Denny M et al:MERIT-HF Study Group:Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension. J Card Fail 8:8-14, 2002

• 26) Kaplan NM:Treatment of coexisting diabetes and hypertension. Curr Cardiol Rep 6:498-503, 2001
  pubmed

• 27) Grundy SM, Howard B, Smith S Jr et al:Prevention Conference VI:Diabetes and cardiovascular disease. Executive summary. Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 105:2231-2239, 2002
  pubmed

• 28) Sawicki PT, Siebenhofer A:Betablocker treatment in diabetes mellitus. J Intern Med 250:11-17, 2001
  pubmed

• 29) UK Prospective Diabetes Study Group:Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39. BMJ 317:713-720, 1998
  Medical*Online

• 30) Chen J, Marciniak TA, Radford MJ et al:Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. Results from the National Cooperative Cardiovascular Project. J Am Coll Cardiol 34:1388-1394, 1999
  pubmed

• 31) Sawicki PS, Siebenhofer A:Beta-blocker treatment in diabetes mellitus. J Int Med 250:11-17, 2001

• 32) Mohacsi P, Fowler MB, Krum H et al:Should physician avoid the use of beta-blockers in patients with heart failure who have diabetes? Results of the COPERNICUS Study (abstr). Circulation 104 (suppl II):S754, 2001

• 33) Deedwania PC, Giles TD, Ghali JK et al:Safety and efficacy of treatment with metoprolol CR/XL in diabetic patients with heart failure (abstr). Circulation 102 (suppl II):S779, 2000

• 34) Ferguson TB Jr, Coombs LP, Peterson ED:Society of Thoracic Surgeons National Adult Cardiac Surgery Database:Preoperative β-blocker use and mortality and morbidity following CABG surgery in North America. JAMA 287:2221-2227, 2002

• 35) Mangano DT, Layug EL, Wallace A et al:Multicenter Study of Perioperative Ischemia Research Group:Effect of atenolol on mortality and cardiovascular morbidity after non-cardiac surgery. N Engl J Med 335:1713-1720, 1996

• 36) Auerbach AD, Goldman L:β-Blockers and reduction of cardiac events in non-cardiac surgery. Scientific review. JAMA 287:1435-1444, 2002

• 37) Mukherjee D, Eagle KA:Perioperative cardiac assessment for noncardiac surgery. Eight steps to the best possible outcome. Circulation 107:2771-2774, 2003

• 38) Fleisher LA, Eagle KA:Lowering cardiac risk in noncardiac surgery. N Engl J Med 345:1677-1682, 2001
  pubmed

• 39) Wink K:Are β-blockers efficacious as first-line therapy for hypertension in the elderly? Curr Hypertens Rep 5:221-224, 2003

• 40) Cleophas T, Van Marum R:Age-related decline in autonomic control of blood pressure:implications for the pharmacological management of hypertension in the elderly. Drugs Aging 20:313-319, 2003
  pubmed

• 41) Somerai SB, McLaughin TJ, Spiegelman D et al:Adverse outcomes of underuse of β-blockers in elderly survivors of acute myocardial infarction. JAMA 277:115-121, 1997

• 42) Williams B, Kim J:Cardiovascular drug therapy in the elderly:theoretical and practical implications. Drugs Aging 20:445-463, 2003

• 43) Law MR, Wald NJ, Morris JK, Jordan RE:Value of low dose combination treatment with blood pressure lowering drugs:analysis of 354 randomised trials. BMJ 326:1427-1431, 2003
  pubmed

• 44) Materson BJ, Reda DJ, Cushman WC et al:Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents:Results of combination antihypertensive therapy after failure of each of the components. J Hum Hypertens 9:791-796, 1995

• 45) Holzgreve H, Nakov R, Beck K et al:Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens 16:381-386, 2003
  pubmed

• 46) Dunder K, Lind L, Zethelius B et al:Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction:population based cohort study. BMJ 326:681-684, 2003
  pubmed

• 47) Hedblad B, Wikstrand J, Janzon L et al:Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from the β-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 103:1721-1726, 2001

• 48) Maak C, Bohm M, Vlaskill L et al:Partial agonist activity of bucindolol is dependent on the activation state of the human β1-adrebergic receptor. Circulation 108:348-353, 2003

• 49) Poole-Wilson PA, Swedberg K, Cleland JGF et al:COMET Investigators:Comparison of carvedilol and metoprolol on clinical out-comes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET):randomized controlled trial. Lancet 362:7-13, 2003

• 50) Hjarmarson A:Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter? Basic Res Cardiol 95 (suppl 1):S41-S45, 2000

• 51) Gheorghide M, Colucci WS, Swedberg K:β-Blockers in chronic heart failure. Circulation 107:1570-1575, 2003

P.125 掲載の参考文献

• 1) The Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure:The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2446, 1997
  pubmed

• 2) Guidelines Subcommittee:1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 17:151-187, 1999
  pubmed

• 3) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2000年版. 日本高血圧学会, 2000

• 4) Chobanian AV, Bakris HR, Black HR et al:the National High Blood Pressure Education Program Coordinating Committee:The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 289:2560-2572, 2003

• 5) Guidelines Committee:2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053, 2003

• 6) Medical Research Council Working Party:MRC trial of treatment of mild hypertension:principal results. BMJ 291:97-104, 1985
  pubmed

• 7) SHEP Cooperative Research Group:Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Eldery Program (SHEP). JAMA 265:3255-3264, 1991

• 8) Dahlof B, Lindholm LH, Hansson L et al:Morbidity and mortality in the Swedish Trial in Old Patients with Hypertention (STOP-Hypertension). Lancet 338:1281-1285, 1991

• 9) Collins R, et al:Blood pressure, stroke, and coronary heart disease. Lancet 335:827-838, 1990
  pubmed

• 10) Messerli F et al:Are β-blockers efficacious as first-line therapy for hypertension in the elderly? JAMA 279:1903-1907, 1998

P.132 掲載の参考文献

• 1) 日本高血圧学会高血圧治療ガイドライン作成委員会編:高血圧治療ガイドライン2000年版 (JSH 2000). 日本高血圧学会, 東京, 2000

• 2) Chobanian AV, Bakris GL, Black HR et al:National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:the JNC 7 report. JAMA 289:2560-2572, 2003

• 3) Guidelines Committee:2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053, 2003

• 4) Kaplan NM:Treatment of hypertension:drug therapy. In:Kaplan's Clinical, Hypertension. Kaplan NM, ed by Lippincott Williams & Wilkins, Philadelphia, 2002, pp.237-338

• 5) 野城孝夫, 三浦幸雄:β遮断薬.日本臨牀 58(増刊号, 高血圧下巻):101-106, 2000

• 6) Frohlich ED:Beta adrenergic blockade in the circulatory regulation of hyperkinetic states. Am J Cardiol 27:195-199, 1971
  pubmed

• 7) Gibbons RJ, Chatterjee K, Daley J et al:ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina). J Am Coll Cardiol 33:2092-2197, 1999

• 8) 勝田洋輔, 今泉勉:β遮断薬・αβ遮断薬.臨床と研究80:22-26, 2003

• 9) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036, 1975
  pubmed

• 10) MERIT-HF Investigators:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999
  pubmed

• 11) Packer M, Bristow MR, Cohn JN et al:U.S. Carvedilol Heart Failure Study Group:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355, 1996

• 12) Beta-Blocker Evaluation of Survival Trial Investigators:A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344:1659-1667, 2001

• 13) CIBIS-II Study Group:The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II):a randomised trial. Lancet 353:9-13, 1999

• 14) Packer M, Coats AJ, Fowler MB et al:Carvedilol Prospective Randomized Cumulative Survival Study Group:Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001

• 15) Poole-Wilson PA, Swedberg K, Cleland JG et al:Carvedilol Or Metoprolol European Trial Investigators:Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET):randomised controlled trial. Lancet 362:7-13, 2003

• 16) Guideline Comittee:Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. J Card Fail 5:357-382, 1999

• 17) Lindholm LH, Ibsen H, Dahlof B et al:LIFE Study Group:Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:1004-1010, 2002

• 18) McFarlane SI, Sowers JR:Treatment of diabetes and hypertension. In:Hypertension Primer. Third ed, eds by Izzo JL, Black HR, Lippincott Williams & Wilkins, Philadelphia, 2003, pp.488-491

• 19) Hansson L, Zanchetti A, Carruthers SG et al:Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755-1762, 1998

• 20) UK Prospective Diabetes Study Group:Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39. BMJ 317:713-720, 1998
  Medical*Online

• 21) Wikstrand J, Warnold I, Olsson G et al:Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 259:1976-1982, 1988
  pubmed

• 22) Messerli FH, Grossman E, Goldbourt U:Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 279:1903-1907, 1998
  pubmed

P.139 掲載の参考文献

• 1) 日本高血圧学会高血圧治療ガイドライン作成委員会編:高血圧治療ガイドライン2000年版, 2000

• 2) Nakaoka H, Kitahara Y, Amano M et al:Effect of beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension. Hypertension 10:221-225, 1987
  pubmed

• 3) Hannedouche T, Landais P, Goldfarb B et al:Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 309:833-837, 1994
  pubmed

• 4) Agodoa LY, Appel L, Bakis GL et al:Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. JAMA 285:2719-2728, 2001

• 5) Bauer JH, Reams GP:Antihypertensive drugs. In:Brenner & Rector's The Kidney. 5th ed, eds by Brenner BM et al, Pennsylvenia, 1996, pp.2231-2381

• 6) 北本清, 長澤俊彦, 猿田享男ほか:高血圧を合併する慢性腎疾患にたいするnipradiolの臨床的有用性-降圧効果, 腎機能および尿蛋白への影響.腎と透析7:115-125, 1999

• 7) 金子裕美, 中岡稔, 藤巻正慶ほか:腎性高血圧に対するCarvedilol (DQ-2446) の長期投与時の有効性ならびに安全性の検討.診断と治療 82:506-522, 1994

• 8) Man in't Veld AJ, Schalekamp MA:Effects of 10 different b-adrenoreceptor antagonists on hemodynamics, plasma renin activity, plasma norepinephrine in hypertension:the key role of vascular resistance changes in relation to partial agonist activity. J Cardiovasc Pharmacol 5 (suppl 1):S30-S 45, 1983

• 9) 吉永馨, 荒川規矩男, 池田正男ほか:褐色細胞腫21例における Labetalol の効果. ホと臨 29:515-522, 1981

• 10) 大石誠一, 佐々木雅人, 森岡由紀ほか:α・β受容体遮断薬(YM-09538) による褐色細胞腫の治療-ラベタロールおよびブナゾシンとの比較-. 臨床と研究64:2274-2250, 1987

• 11) Briggs RS, Birtwell AJ, Pohl JE:Hypertensive response to labetalol in pheochromocytoma. Lancet 13:1045-1046, 1987

• 12) Reach G, Thibonnier M, Chevillard CP et al:Effect of labetalol on blood pressure and plasma catecholamine concentrations in patients with pheochromocytoma. BMJ 280:1300-1301, 1980

• 13) Ramsay L, Williams B, Johnston G et al:Guidelines for management of hypertension:report of the third working party of the British Hypertension Society. J Hum Hypertens 13:569-592, 1999
  pubmed

• 14) National High Blood Pressure Education Program:Report of the National High Blood Pressure Education Program Group on high blood presuure in pregnancy. Am J Obstet Gynecol 183 (suppl 1):S1-S 22, 2000

• 15) 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 17:151-183, 1999
  pubmed

P.144 掲載の参考文献

• 1) 村田和子, 齊藤郁夫:血圧のトラッキング現象. 日本臨牀58(増刊号:下):397-410, 2000

• 2) Kaplan NM:Clinical Hypertension, Williams and Wilkins, Baltimore, 2002, pp.137

• 3) 齊藤郁夫:若年者の高血圧の病態と管理の実際. Medical Practice 19:1515-1517, 2002
  Medical*Online

• 4) Nishibata K, Nagashima M, Tsuji A et al:Comparison of casual blood pressure and twenty-four-hour ambulatory blood pressure in high school students. J Pediatr 127:34-39, 1995
  pubmed

• 5) 三浦幸雄, 野城孝夫, 川崎晃一ほか:大学生における血圧の現状:定期健康診断からみえる心血管系リスク因子. 日本臨牀58(増刊号) (上):627-631, 2000

• 6) Saito I, Imai Y, Shimada K et al.:Prevalence of and causative factors in white-coat hypertension:results of the Japanese multicenter study on Barnidipine with ambulatory blood pressure monitoring. Blood Press Monitor 6 (suppl 2):S17-S 23, 2001

• 7) Saito T, Saito I, Nanri S et al.:A quantitative evaluation of the effects of sex and age on the positivity of family history of hypertension. J Epidemiol 8:99-105, 1998
  pubmed

• 8) Hirose H, Saito I, Tsujioka M et al.:The obese gene product, leptin:possible role in obesity-related hypertension in adolescents. J Hypertens 16:2007-2012, 1998
  pubmed

• 9) 齊藤郁夫:高血圧とインスリン抵抗性.日内会誌, 90:1744-1747, 2001

• 10) Kawabe H, Shibata H, Hirose H et al.:Determinants for the development of hypertension in adolescents. A 6-year follow-up. J Hypertens 18:1557-1561, 2000
  pubmed

• 11) Hirose H, Saito I, Kawai T et al.:Relationships between baseline serum leptin levels and 2-year changes in body mass index, blood pressure and metabolic parameters in Japanese male adolescents and middle-aged men. Clin Sci 100:145-150, 2001
  pubmed

• 12) 日本高血圧学会高血圧治療ガイドライン作成委員会編:実地医家のための高血圧治療ガイドライン, 学会出版センター, 東京, 2001, p.15

• 13) Brown MJ, Cruickshank JK, Dominiczak AF et al.:Better blood pressure control:how to combine drugs. J Hum Hypertens 17:81-86, 2003
  pubmed

P.150 掲載の参考文献

• 1) 厚生統計協会:健康状態と受療状況, 生活習慣病対策.国民衛生の動向・厚生の指標45:81-111, 1998

• 2) Insua JT, Sacks HS, Lau T-S et al:Drug treatment of hypertension in the elderly. A meta-analysis. Ann Intern Med 121:355-362, 1994
  pubmed

• 3) Staessen JA, Gasowski J, Wang JG et al:Risks of untreated and treated isolated systolic hypertension in the elderly:meta-analysis of outcome trials. Lancet 355:865-872, 2000
  pubmed

• 4) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036, 1975
  pubmed

• 5) Neal B, MacMahon S, Chapman N:Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs:results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 356:1955-1964, 2000
  pubmed

• 6) Messerli FH, Grossman E, Goldbourt U:Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 279:1903-1907, 1998

• 7) Madhavan S, Ooi WL, Cohen H et al:Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 23:395-401, 1994

• 8) Dahlof B, Lindholm L, Hansson L:Mobidity and mortality in the Swedish trial in old patients with hypertension. STOP-Hypertension. Lancet 338:1281-1285, 1991

• 9) Morgan TO, Anderson AI, Maclnnis RJ:ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 14:241-247, 2001

• 10) Wilhelmsen L, Berglund G, Elmfedt D et al:Beta-blockers versus diuretics in hypertensive men:main results from the HAPPHY trial. J Hypertens 5:561-572, 1987

• 11) Wikstrand J, Warnold I, Toumilehto J et al:Metoprolol versus diuretics in hypertension. Morbidity results from the MAPHY study. Hypertension 17:579-588, 1991

• 12) Coope J, Warrender TS:Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J 293:1145-1152, 1986

• 13) MRC Working Party:Medical Research Council trial of treatment of hypertension in older adult:principal results. B M J 304:1406-1416, 1992

• 14) SHEP Cooperative Research Group:Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA 265:3255-3264, 1991

• 15) Kaplan NM:The place for beta-blockers in treating hypertension. Eur Heart J 20:5-6, 1999
  pubmed

• 16) Dahlof B, Devereux RB, Kjeldsen SE et al:Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE):a randomized trial against atenolol. Lancet 359:995-1003, 2002
  pubmed

• 17) Cruickshank JM:Losartan for cardiovascular disease in patient's with and without diabetes in LIFE study. Lancet 359:2200-2201, 2002

• 18) Yusuf S, Peto R, Lewis J, et al:Beta blockade during and after myocardial infarction:an overview of the randomized study. Prog Cardiovasc Dis 27:335-342, 1985

• 19) Soumerai SB, McLaughlin TJ, Spiegelman D et al:Adverse outcomes of underuse of β-blockers in elderly survivors of acute myocardial infarction. JAMA 277:115-121, 1997

• 20) β-Blocker Heart Attack Trial Research Group:A randomized trial of propranolol in patients with acute myocardial infarction I:mortality results. JAMA 247:1707-1714, 1982

• 21) The Norwegian Multicenter Study:Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Eng J Med 304:801-807, 1981

• 22) Chen J, Marciniak TA, Radford MJ et al:Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. J Am Coll Cardiol 34:1388-1394, 1999
  pubmed

P.156 掲載の参考文献

• 1) Millar-Craig MW, Mann S, BalaSubramanian V et al:The effect of oxprenolol on ambulatory intra-arterial blood pressure in essential hypertension. Eur J Clin Pharmacol 24:713-721, 1983

• 2) Raftery EB, Mann S, BalaSubramanian V et al:Once-daily pindrol in hypertension:an ambulatory assessment. Am Heart J 104:417-420, 1982
  pubmed

• 3) 藤井嘉人, 栃久保修, 石井當男ほか:血圧・脈拍数の日内変動に及ぼすBopindlolの影響-本態性高血圧症外来患者での検討-. Therap Res 10:2533-2542, 1989

• 4) Kuwajima I, Suzuki Y, Kuramoto K et al:Circadian blood pressure change after carteolol chloride in younger and older hypertensive patients. Clin Ther 15:338-346, 1993
  pubmed

• 5) 小竹親夫, 小屋祐司, 池田宗一郎ほか:本態性高血圧に対するacebutololおよびmetoprolol の効果.特に日内変動に対する効果. 呼と循 40:885-890, 1992

• 6) Neutel JM Schnaper S, Cheung DG et al:Antihypertensive effects of β-blockers administered once daily:24-hour measurements. Am Heart J 120:166-171, 1990

• 7) Parati G, Pomidossi G, Casadei R et al:Evaluation of the antihypertensive effect of celiprolol by ambulatory blood pressure monitoring. Am J Cardiol 61 (suppl C):S27-S33, 1988

• 8) Rustin MH, Coomes EN:Comparison of propranolol and propranolol LA in hypertension using 24-hr non-invasive blood pressure monitoring. Postgrad Med J 59:770-774, 1983

• 9) Mann S, Craig MW, BalaSubramanian V et al:Propranolol LA and ambulatory blood pressure. Br J Clin Pharmacol 10:443-447, 1980
  pubmed

• 10) Mancia G, Ferrari A, Pomidossi G et al:Twenty-four-hour blood pressure profile and blood pressure variability in untreated hypertension and during antihypertensive treatment by once-a-day nadolol. Am Heart J 108:1078-1083, 1984

• 11) Hornung RS, Gould BA, Kieso H, Raftery EB et al:A study of nadolol to determine its effect on ambulatory blood pressure over 24 hours, and during exercise testing. Br J Clin Pharmacol 14:83-88, 1982
  pubmed

• 12) 林博史, 松波龍幸, 平井真理ほか:24時間血圧変動から見た本態性高血圧に対するNipradilol(ハイパジール) の効果. Therap Res 12:3545-3554, 1991

• 13) Mann S, Craig MW, Altman DG et al:The effects of metoprolol on ambulatory blood pressure. Clin Sci 57 (suppl 1):S375-S 377, 1979

• 14) Raftery EB, Mann S, Millar-Craig M et al:Effect of once-daily atenolol on ambulatory blood pressure. B M J:237-238, 1979

• 15) Graettinger WF, Lipson JL, Klein RC et al:Comparison of antihypertensive therapies by noninvasive techniques. Chest 96:74-79, 1989
  pubmed

• 16) 劉会中, 田村潔, 三浦甫ほか:塩酸ベタキソロールの使用経験-多類多群β遮断薬とのクロスオーバー比較試験-第1報:随時・日内変動から見た長期投与の有効性と安全性. 臨床と研究 75:1209-1221, 1998

• 17) Al-Khawaja IM, Caruana MP, Prince H et al:Once-and twice-daily bevantolol for systemic hypertension using 24-hour ambulatory intraarterial blood pressure recording. Am J Cardiol 58 (suppl E):S17-S 20, 1986

• 18) BalaSubramanian V, Mann S, Raftery EB et al:Effect of labetalol on continuous ambulatory blood pressure. Br J Clin Pharmacol 8 (suppl 2):S119-S 123, 1979

• 19) 塩見利明, 小林正, 矢野弓子ほか:本態性高血圧症外来患者における血圧の日内変動・日内リズムに対するarotinolol hydrochlorideの影響-非観血型携帯型自動血圧計による1日1回投与と1日2回分割投与の比較-. 循環器科26:345-353, 1989

• 20) Palatini P, Sperti G, Cordone L et al:Twenty four-hour continuous in direct blood pressure monitoring during treatment with slow release metoprolol and atenolol. Acta Ther 12:23-32, 1986

• 21) Wu H, Zhang Y, Huang J et al:Clinical trial of arotinolol in the treatment of hypertension:dippers vs. non-dippers. Hypertens Res 24:605-610, 2001
  pubmed

• 22) 相馬正義, 福田昇, 泉洋一ほか:塩酸ベタキソロールの血圧日内変動, レニン-アンジオテンシン-アルドステロン系, 腎機能, 糖代謝及び脂質代謝に対する効果について. 薬理と治療 25:1186-1193, 1997

• 23) 小林和夫, 上村精一郎, 飯田武史ほか:本態性高血圧症に対するβ遮断薬カルバン錠(塩酸ベバントロール) の長期投与における血圧日内変動および心機能に及ぼす影響-dipper型と non-dipper型との比較-. 臨床と研究80:787-798, 2003

Part 5/ 合併症を伴った高血圧とβ遮断薬

P.163 掲載の参考文献

• 1) 泰江弘文:虚血性心疾患の分類とその意義. 臨床医9:1613-1616, 1999

• 2) Fuster V, Badimon L, Badimon JJ et al:The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 326:242-250, 1992
  pubmed

• 3) 泰江弘文:狭心症の概念と分類. 循環器科44:109-112, 1998

• 4) Yasue H, Omote S, Takizawa A et al:Exertional angina pectoris caused by coronary arterial spasm:effects of various drugs. Am J Cardiol 43:647-652, 1979
  pubmed

P.170 掲載の参考文献

• 1) 大久典子, 吉田克己, 加賀満夫:早朝高血圧の心拍変動解析. 臨床病理51:414-418, 2003

• 2) Siegel D, Black DM, Seeley D et al:Circadian variation in ventricular arrhythmia in hypertensive men. Am J Cardiol 69:344-347, 1992
  pubmed

• 3) Esler M:The sympathetic system and hypertension. Am J Hypertens 13 (suppl 1):S99-S105, 2000

• 4) Coumel P:Cardiac arrhythmia and the autonomic nervous system. J Cardiovasc Electrophysiol 4:338-355, 1993
  pubmed

• 5) Ciaroni S:Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension. Am Heart J 139:814-819, 2000
  pubmed

• 6) Tomita F, Kohya T, Sakurai M et al:Hokkaido Atrial Fibrillation Study Group:Prevalence and clinical characteristics of patients with atrial fibrillation:analysis of 20,000 cases in Japan. Jpn Circ J 64:653-658, 2000

• 7) Stroke Prevention in Atrial Fibrillation Investigators:Predictors of thromboembolism in atrial fibrillation:II. Echocardiographic features of patients at risk. Ann Intern Med 116:6-12, 1992
  pubmed

• 8) Coumel P:Autonomic influences in atrial tachyarrhythmias. J Cardiovasc Electrophysiol 7:999-1007, 1996
  pubmed

• 9) Van Gelder IC, Hagens VE, Bosker HA et al:Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group:A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:1834-1840, 2002

• 10) Wyse DG, Waldo AL, Di Marco JP et al:Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825-1833, 2002

• 11) Fuster V, Ryden LE, Asinger RW et al:ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation:Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 104:2118-2150, 2001

• 12) David D, Di Segni E, Klein HO et al:Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation:beneficial effects of an added beta-adrenergic blocking agent. Am J Cardiol 44:1378-1382, 1979

• 13) Farshi R, Kistner D, Sarma JS et al:Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise:a crossover open-label study of five drug regimens. J Am Coll Cardiol 33:304-310, 1999
  pubmed

• 14) Reiter M:β-adrenergic blocking drugs as antifibrillatory agents. Curr Cardiol Rep 4:426-433, 2002

• 15) Steeds RP, Birchall AS, Smith M et al:An open label, randomized crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart 82:170-175, 1999
  pubmed

• 16) Tieleman RG, Van Noord T, Van Gelder IC et al:Beta-blockers prevent subacute recurrences after cardioversion from persistent atrial fibrillation in patients with hypertension but not in lone atrial fibrillation patients (abstr). PACE 24:675, 2001
  pubmed

• 17) McLenachan JM, Henderson E, Morris KI et al:Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 317:787-792, 1987
  pubmed

• 18) Galinier M, Balanescu S, Fourcade J et al:Prognostic value of ventricular arrhythmias in systemic hypertension. J Hypertens 15:1779-1783, 1997
  pubmed

• 19) Salerno DM, Gillingham KJ, Berry DA et al:A comparison of antiarrhythmic drugs for the suppression of ventricular ectopic depolarizations:a meta-analysis. Am Heart J 120:340-353, 1990
  pubmed

• 20) Toyoshima H, Park YD, Ishikawa Y et al:Effects of ventricular hypertrophy on conduction velocity of activation front in the ventricular myocardium. Am J Cardiol 49:1938-1845, 1982
  pubmed

• 21) Schmieder RE:Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 13:564-569, 1998
  pubmed

• 22) Mayet J, Shahi M, Poulte NR et al:Ventricular arrhythmias in hypertension:in which patients do they occur? J Hypertens 13:269-276, 1995

• 23) O'Gorman DJ, Sheridan DJ:Abnormalities of coronary circulation associated with left ventricular hypertrophy. Clin Sci 81:703-713, 1991
  pubmed

• 24) Meredith IT, Broughton A, Jennings GL et al:Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 325:618-624, 1991
  pubmed

• 25) Kuwajima I, Mitani K, Miyao M et al:Cardiac implications of the morning surge in blood pressure in elderly hypertensive patients:relation to arising time. Am J Hypertens 8:29-33, 1995
  pubmed

• 26) Behrens S, Ehlers C, Bruggemann T et al:Modification of the circadian pattern of ventricular tachyarrhythmias by beta-blocker therapy. Clin Cardiol 20:253-7, 1997
  pubmed

• 27) Dodt C, Breckling U, Derad I et al:Plasma epinephrine and norepinephrine concentrations of healthy humans associated with nighttime sleep and morning arousal. Hypertension 30:71-76, 1997
  pubmed

• 28) Bayes de Luna A, Coumel P, Leclercq JF:Ambulatory sudden cardiac death:mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 117:151-159, 1989
  pubmed

• 29) Bayes-Genis A, Guindo J, Vinolas X et al:Cardiac arrhythmias and left ventricular hypertrophy in systemic hypertension and their influences on prognosis. Am J Cardiol 76:54D-59 D, 1995

• 30) The Cardiac Arrhythmia Suppression Trial-II investigators:The effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327:227-233, 1992
  pubmed

• 31) Peters RW, Muller JE, Goldstein S et al:Propranolol and the morning increase in the frequency of sudden cardiac death (BHAT). Am J Cardiol 63:1518-1520, 1989

• 32) Kendall MJ:Clinical relevance of pharmacokinetic differences between beta blockers. Am J Cardiol 80:15J-19 J, 1997
  pubmed

• 33) Lindholm LH, Dahlof B, Edelman JM et al:LIFE study group:Effect of losartan on sudden cardiac death in people with diabetes:data from the LIFE study. Lancet 362:619-620, 2003

P.176 掲載の参考文献

• 1) Cortes P, Riser BL, Zhao X et al:Glomerular volume expansion and mesangial cell mechanical strain-mediators of glomerular pressure injury-. Kidney Int 45 (suppl 1):S11-S 16, 1994

• 2) Anderson S, Brenner BM:Progressive renal disease:a disorder of adaptation. Q J Med 70:185-189, 1989
  pubmed

• 3) Arendshorst WJ, Navar LG:Renal circulation and glomerular hemodynamics. In:Textbook of The Kidney, 4th ed, eds by Schrier RW, Gottschalk CW, Little Brown, Boston, 1998, pp.63-117

• 4) de Jong PE, Anderson S, de Zeeuw D:Glomerular preload and after load reduction as tool to lower urinary protein leakage:will such treatments also help to improve renal function outcome? J Am Soc Nephron 3:1333-1341, 1993

• 5) Nakamura T, Obata J, Kimura H et al:Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int 55:877-889, 1999
  pubmed

• 6) Klahr S, Levey AS, Beck GJ et al:The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330:877-884, 1994
  pubmed

• 7) Peterson JC, Adler S, Burkart JM et al:Blood pressure control, proteinuria and the progression of renal disease. Ann Intern Med 123:754-762, 1995
  pubmed

• 8) 木村玄次郎:腎と高血圧, 病態生理からのアプローチ, 東京医学社, 東京, 1998

• 9) Praga M, Hernandez E, Montoyo C et al:Long-term beneficial effect of angiotensin-converting enzyme inhibition in patients with nephritic proteinuria. Am J Kidney Dis 20:240-248, 1992

• 10) Gansevoort RT, de Zeeuw D, de Jong PE:Long-term benefits of the antiproteinuric effect of angiotensin-converteing enzyme inhibition in non-diabetic renal disease. Am J Kidney Dis 22:202-206, 1993

• 11) Apperloo AJ, de Zeeuw D, de Jong PE:A short-term antihypertensive treatment-induced in fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 51:793-797, 1997

• 12) The GISEN Group:Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
  pubmed

• 13) Ruggeneti P, Perna A, Mosconi L et al:Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int 53:1209-1216, 1998
  pubmed

• 14) Misu Y, Kubo T:Presynaptic beta-adrenoreceptors and hypertension. In:Presynaptic regulation of Neurotransmitter release:A Handbook, eds by Feigenbaum J, Hanamim Freund Publishing House, London, 1991

• 15) Van Beek MA, Struyker Boudier HAJ, Smits JFM:Antihypertensive mechanism of beta-adrenoreceptor blockade:A review. Clin Exp Theory Practice A 7:1-72, 1985

• 16) Mark AL, Eckstein JW, Abboud FM et al:Renal vascular responsed to isoproterenol. Am J Physiol 217:764-767, 1969

• 17) Hannedouche T, Landais P, Goldfarb et al:Randomized controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 309:833-837, 1994
  pubmed

• 18) Garg J, Bakris GL:Treatment of hypertension in patients with renal disease. Cardiovasc Drugs Ther 16:503-510, 2002
  pubmed

• 19) 北本清, 長澤俊彦, 猿田享男ほか:高血圧を合併する慢性腎疾患に対するnipradilolの臨床的有用性-降圧効果, 腎機能および尿蛋白への影響. 腎と透析473:115-125, 1999

• 20) Takamitsu Y, Nakanishi T et al:A nitric oxide-generating beta-blocking agent prevents renal injury in the rat remnant kidney model. Nephron Physiol 93:42-50, 2003

• 21) Kalinowski L, Dobrucki LW, Szczepanska-Konkel M et al:Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux:novel mechanism for antihypertensive action. Circulation 107:2747-2752, 2003
  pubmed

• 22) Nakamoto H, Nemoto H, Sugihara S et al:Nifedipine and arotinolol in combination for accerelated malignant hypertension:result of one year follow-up. Hypertens Res 22:75-80, 1999

• 23) Hall WD, Kusek JW, Kirk KA et al:Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate:The African-American Study of Kidney Disease and Hypertension Pilot Study. Am J Kidney Dis 29:720-728, 1997
  pubmed

• 24) Agodoa LY, Appel L, Bakris GL et al:Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis:a randomized controlled trial. JAMA 285:2719-2728, 2001
  pubmed

• 25) Wright JT Jr, Bakris G, Greene T et al:Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease:results from the AASK trial. JAMA 288:2421-2431, 2002
  pubmed

• 26) Sica DA:The African American Study of Kdiney Disease and hypertension (AASK) trial:What more have we learned? J Clin Hypertens (Greenwich) 5:159-167, 2003

• 27) Fukuda M, Usami T, Yoshida A et al:Antihypertensive drug and renal protection. JAMA 289:1102-1103, 2003
  pubmed

• 28) The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. NIH Publication No.03-5233, 2003

• 29) Chrysant SG:The ALLHAT study:results and clinical implications. Q J Med 96:771-773, 2003

• 30) Swedish Lisinopril Study Group:Lisinopril combined with atenolol in the treatment of hypertension. J Cardiovasc Pharmacol 18:457-461, 1991

• 31) Soininen K, Gerlin-Piira L, Suihkonen J et al:A study of the effects of lisinopril when used in addition to atenolol. J Hum Hypertens 6:321-324, 1992
  pubmed

• 32) Aurell M, Bengtsson C, Bjorck S Enalapril versus metoprolol in primary hypertension-effects on the glomerular filtration rate. Nephron Dial Transplant 12:2289-2294, 1997

P.183 掲載の参考文献

• 1) National Institute of Neurological Disorders and Stroke Ad Hoc Committee:Classification of cerebrovascular disease III. Stroke 21:637-676, 1990

• 2) Schrader J, Luders S, Kulschewski A et al:the ACCESS Study Group:The ACCESS Study:evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 34:1699-1703, 2003

• 3) Irie K, Yamaguchi T, Minematsu K et al:The J-curve phenomenon in stroke recurrence. Stroke 24:1844-1849, 1993

• 4) PROGRESS Collaborative Group:Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 358:1033-1041, 2001
  pubmed

• 5) Chobanian AV, Bakris HR, Black HR et al:the National High Blood Pressure Education Program Coordinating Committee:The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289:2560-2572, 2003

• 6) Lysko PG, Lysko KA, Yue TL et al:Neuroprotective effects of carvedilol, a new antihypertensive agent, in cultured rat cerebellar neurons and in gerfil global brain ischemia. Stroke 23:1630-1636, 1992
  pubmed

• 7) Kuriyama Y, Nakamura M, Kyougoku I et al:Effects of carvedilol on cerebral blood flow and its autoregulation in previous stroke patients with hypertension. Eur J Clin Pharmacol 38:S 120-S 121, 1990

• 8) Coope J, Warrender TS:Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ 293:1145-1151, 1986
  pubmed

• 9) MRC Working Party:MRC trial of treatment of mild hypertension:principal results. BMJ 291:97-104, 1985
  pubmed

• 10) Wilhelmsen L, Berglund G, Elmfeldt D et al:Beta-blocker versus diuretics in hypertensive men:main results from the HAPPHY trial. J Hypertens 5:561-572, 1987

• 11) Wilkstrand J, Warnord I, Olsson G et al:Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 259:1976-1982, 1988

• 12) Dahlof B, Lindholm LH, Hansson L et al:Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338:1281-1285, 1991
  pubmed

• 13) Hansson L, Lindholm LH, Ekbom T et al:STOP-Hypertension-2 study group:Randomized trial of old and new antihypertensive drugs in elderly patients:cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354:1751-1756. 1999

• 14) Messeri FH, Grossman E, Goldbourt U:Are β-blockers efficacious as first-line therapy for hypertension in the elderly?:A systematic review. JAMA 279:1903-1907. 1998

• 15) Dahlof B, Devereux RB, Kjeldsen SE et al:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomized trial against atenolol. Lancet 359:995-1003, 2002
  pubmed

• 16) MRC Working Party:Medical Research Council trial of treatment of hypertension in older adults:principal results. BMJ 304:405-412, 1992
  pubmed

• 17) Palatini P, Casiglia E, Pauletto P et al:Relationship of tachycardia with high blood pressure and metabolic abnormalities:a study with mixture analysis in three populations. Hypertension 30:1267-1273, 1997
  pubmed

• 18) Hedblad B, Wikstrand J, Janzon L et al:Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness:main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 103:1721-1726, 2001
  pubmed

• 19) Bots ML, Hoes AW, Koudstaal PJ et al:Common carotid intima-media thickness and risk of stroke and myocardial infarction:The Rotterdam Study. Circulation 96:1432-1437, 1997
  pubmed

• 20) Sabbah HN, Khaja F, Hawkins ET et al:Relation of atherosclerosis to arterial wall shear in the left anterior descending coronary artery of man. Am Heart J 112:453-458, 1986

• 21) Wikstrand J, Berglund G, Hedblad B et al:Antiatherosclerotic effects of β-blockers. Am J Cardiol 91 (12 A):H 25-H 29, 2003

• 22) Kario K, Pickering TG, Umeda Y et al:Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives:a prospective study. Circulation 107:1401-1406, 2003
  pubmed

• 23) Pickering TG, Levenstein M, Walmsley P et al:Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT study. Am J Hypertens 7:986-990, 1994

• 24) BalaSubramanian V, Mann S, Millar-Craig MW et al:Effect of Labetalol on continuous ambulatory blood pressure. Br J Clin Pharmacol 8 (suppl 2):S 119-S 123, 1979

• 25) Black HR, Elliott WJ, Grandits G et al for the CONVINCE Research Group:Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA 289:2073-2082, 2003

• 26) Smith DH, Neutel JM, Weber MA:A new chronotherapeutic oral drug absorption system for verapamil optimizes blood pressure control in the morning. Am J Hypertens 14:14-19, 2001
  pubmed

P.191 掲載の参考文献

• 1) 日本高血圧学会高血圧治療ガイドライン作成委員会編:高血圧治療ガイドライン2000年版, 2000

• 2) Chobanian AV, Bakris GL, Black HR et al:The National High Blood Pressure Education Program Coordinating Committee:The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:The JNC 7. JAMA 289:2560-2572, 2003

• 3) Guidleine Committee:2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053, 2003

• 4) American Diabetes Association:Treatment of hypertension in adults with diabetes. Diabetes Care 25:199-201, S 71-S 89, 2002

• 5) 片山茂裕, 盛田俊介:糖尿病患者に対する循環器薬の使い方. Cardiologist 4:367-371, 1999

• 6) Hansson L, Lindholm LH, Niskanen L et al:Captopril Prevention Project (CAPPP) study group:Effect of angiotensin-converting-enzyme inhibition compared with conventional morbidity and mortality in hypertension:the Captopril Prevention Project (CAPPP) randomized trial. Lancet 353:611-616, 1999

• 7) Lindholm L, Ibsen H, Dahlof B et al:LIFE study group:Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:1004-1010, 2002

• 8) Kosegawa I, Inaba M, Morita T et al:Effects of the vasodilatory β-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension. Clin Exp Hypertens 20:751-761, 1998

• 9) Jacob S, Rett K, Wicklmayr M et al:Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity:the carvedilol-metoprolol study. J Hypertens 14:489-494, 1996
  pubmed

• 10) Giugliano D, Acampora R, Marfella R et al:Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. Ann Intern Med 126:955-959, 1997
  pubmed

• 11) Lithell H, Anderson P-E:Metabolic effects of carvedilol in hypertensive patients. Eur J Pharmacol 52:13-17, 1997

• 12) Packer M, Bristow M, Cohn JN et al:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355, 1996
  pubmed

• 13) Shorr RI, Ray WA, Daugherty JR et al:Antihypertensive and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 278:40-43, 1997
  pubmed

• 14) Curb JD, Pressel SL, Culter JA et al:the Systolic Hypertension in the Elderly Program Cooperative Research Group:Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 276:1886-1892, 1996

• 15) UK Prospective Diabetes Study (UKPDS) Group:Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38. BMJ 317:703-713, 1998
  Medical*Online
  pubmed

• 16) UK Prospective Diabetes Study (UKPDS) Group:Efficacy of atenolol and captopril in reduction risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39. BMJ 317:713-720, 1998
  pubmed

• 17) Lindholm LH, Hansson L, Ekbom T et al for the STOP Hypertension-2 Study Group:Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients:results from the Swedish Trial in Old Patients with Hypertension-2. J Hypertens 18:1671-1675, 2000

• 18) Niskanen L, Lanke J, Hedner T et al for the CAPPP study group:Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compare with diuretic/β-blocker-based treatment regimen. A subanalysis of the Captopril Prevention Project. Diabetes Care 24:2091-2096, 2001

• 19) Kjekshus J, Gilpin E, Cali G et al:Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 11:43-50, 1990
  pubmed

• 20) Joans M, Reicher-Reiss H, Boyko V et al:Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Cardiol 77:1273-1277, 1996

P.197 掲載の参考文献

• 1) Leren P, Helgeland A, Hjermann I et al:The Oslo study:CHD risk factors, socio-economic influences, and intervention. Am Heart J 106:1200-1206, 1983

• 2) Gersh BJ, Braunwald E, Bonow RO:Chronic coronary artery disease. In:Heart Disease:A Textbook of Cardiovascular Medicine 6th ed. eds by Braunwald E, Zipes D, Libby P, WB Saunders Company, Philadelphia, 2001, pp.1290-1293

• 3) Kasiske BL, Ma JZ, Kalil RS et al:Effect of antihypertensive therapy on serum lipids. Ann Intern Med 122:133-141, 1995

• 4) Fogari R, Zoppi A, Corradi L et al:Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 33:534-539, 1999
  pubmed

• 5) Goto Y, Tamachi H, Fusegawa Y et al:Effects of carvedilol on serum lipids in patients with essential hypertension. J Cardiovasc Pharmacol 18 (suppl 4):S 45-S 50, 1991

• 6) Whittington-Coleman PJ, Carrier O Jr, Douglas BH:The effects of propranolol on cholesterol-induced atheromatous lesions. Atherosclerosis 18:337-345, 1973
  pubmed

• 7) Chobanian AV, Brecher P, Chan C:Effects of propranolol on atherogenesis in the cholesterol-fed rabbit. Circ Res 56:755-762, 1985
  pubmed

• 8) Hurt E, Camejo G:Effect of arterial proteoglycans on the interaction of LDL with human monocyte-derived macrophages. Atherosclerosis 67:115-126, 1987
  pubmed

• 9) Nishimiya T, Daniell HB, Webb JG et al:Chronic treatment with propranolol enhances the synthesis of prostaglandins E 2 and I 2 by the aorta of spontaneously hypertensive rats. J Pharmacol Exp Ther 253:207-213, 1990
  pubmed

• 10) Feuerstein GZ, Ruffolo RR Jr:Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J 17 (suppl B):S 24-S 29, 1996

• 11) Maggi E, Marchesi E, Covini D et al:Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 27:532-538, 1996
  pubmed

• 12) Sugawara H, Tobise K, Kikuchi K:Antioxidant effects of calcium antagonists on rat myocardial membrane lipid peroxidation. Hypertens Res 19:223-228, 1996

• 13) Guideline Subcommittee of the WHO-ISH Mild Hypertension Liaison Committee:1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 17:151-183, 1999

• 14) 日本高血圧学会高血圧治療ガイドライン作成委員会:臓器障害を合併する高血圧の治療. 高血圧治療ガイドライン2000年版(日本高血圧学会高血圧治療ガイドライン作成委員会編), 日本高血圧学会, 2000, p.45

• 15) Chobanian AV, Bakris GL, Black HR et al:The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:the JNC 7 report. JAMA 289:2560-2572, 2003
  pubmed

• 16) Guidelines Committee:2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053, 2003

• 17) Wiklund O, Hulthe J, Wikstrand J et al:Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia:a 3-year randomized study. Stroke 33:572-577, 2002
  pubmed

• 18) Gadowski GR, Pilcher DB, Ricci MA:Abdominal aortic aneurysm expansion rate:effect of size and beta-adrenergic blockade. J Vasc Surg 19:727-731, 1994

• 19) Brophy C, Tilson JE, Tilson MD:Propranolol delays the formation of aneurysms in the male blotchy mouse. J Surg Res 44:687-689, 1988
  pubmed

• 20) Radack K, Deck C:β-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 151:1769-1776, 1991

• 21) Yusuf, S, Peto R, Lewis J et al:Beta blockade during and after myocardial infarction:an overview of the randomized trials. Prog Cardiovasc Dis 27:335-371, 1985
  pubmed

Part 6/ 虚血性疾息治療薬としてのβ遮断薬

P.208 掲載の参考文献

• 1) Kuzuya K, Hoshida S, Kim Y et al:Detection of oxygen-derived free radical generation in the canine postischemic heart during late phase of reperfusion. Circ Res 66:1160-1165, 1990

• 2) Neely JR, Grotyohann LW:Role of glycolytic products in damage to ischemic myocardium. Dissociation of adenosine triphosphate levels and recovery of function of reperfused ischemic hearts. Circ Res 55:816-824, 1984
  pubmed

• 3) Gross GJ, Farber NE, Hardman HF et al:Beneficial actions of superoxide dismutase and catalase in stunned myocardium of dogs. Am J Physiol 250:H 372-H 377, 1986

• 4) Bolli R, Jeroudi MO, Patel BS et al:Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion. Evidence that myocardial "stunning" is a manifestation of reperfusion injury. Circ Res 65:607-622, 1989
  pubmed

• 5) Marban E, Kitakaze M, Koretsune Y et al:Quantification of [Ca2+] i in perfused hearts. Critical evaluation of the 5 F-BAPTA and nuclear magnetic resonance method as applied to the study of ischemia and reperfusion. Circ Res 66:1255-1267, 1990

• 6) Sato H, Hori M, Kitakaze M et al:Reperfusion after brief ischemia disrupts the microtubule network in canine hearts. Circ Res 72:361-375, 1993
  pubmed

• 7) Kusuoka H, Porterfield JK, Weisman HF et al:Pathophysiology and pathogenesis of stunned myocardium. Depressed Ca2+activation of contraction as a consequence of reperfusion-induced cellular calcium overload in ferret hearts. J Clin Invest 79:950-961, 1987
  pubmed

• 8) Hori M, Kitakaze M, Sato H et al:Staged reperfusion attenuates myocardial stunning in dogs. Role of transient acidosis during early reperfusion. Circulation 84:2135-2145, 1991
  pubmed

• 9) Kitakaze M, Weisfeldt ML, Marban E:Acidosis during early reperfusion prevents myocardial stunning in perfused ferret hearts. J Clin Invest 82:920-927, 1988
  pubmed

• 10) Kitakaze M, Weisman HF, Marban E:Contractile dysfunction and ATP depletion after transient calcium overload in perfused ferret hearts. Circulation 77:685-695, 1988
  pubmed

• 11) Pike MM, Kitakaze M, Marban E:23Na-NMR measurements of intracellular sodium in intact perfused ferret hearts during ischemia and reperfusion. Am J Physiol 259:H 1767-H 1773, 1990

• 12) Murphy AM, Kogler H, Georgakopoulos D et al:Transgenic mouse model of stunned myocardium. Science 287:488-491, 2000
  pubmed

• 13) Schofer J, Montz R, Mathey DG:Schintigraphic evidence of the no reflow phenomenon in human being after coronary thrombolysis. J Am Coll Cardiol 5:593-598, 1985
  pubmed

• 14) Yusuf S, Peto R, Lewis J et al:Beta blockade during and after myocardial infarction:an overview of the randomized trials. Prog Cardiovasc Dis 27:335-371, 1985
  pubmed

• 15) Murray KT, Reilly C, Koshakji RP et al:Suppression of ventricular arrhythmias in man by d-propranolol independent of beta-adrenergic receptor blockade. J Clin Invest 85:836-842, 1990

• 16) Sheridan DJ, Penkoske PA, Sobel BE et al:Alpha adrenergic contributions to dysrhythmia during myocardial ischemia and reperfusion in cats. J Clin Invest 65:161-171, 1980

• 17) Asanuma H, Kitakaze M, Node K et al:Celiprolol increases coronary blood flow and reduces the severity of myocardial ischemia via nitric oxide release. J Cardiovasc Pharmacol 41:499-505, 2003
  pubmed

• 18) Gao F, Chen J, Lopez BL et al:Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. Eur J Pharmacol 406:109-116, 2000

• 19) Kitakaze M, Hori M, Takashima S et al:Superoxide dismutase enhances ischemia-induced reactive hyperemic flow and adenosine release in dogs:a role of 5'-nucleotidase activity. Circ Res 71:558-566, 1992
  pubmed

• 20) Asanuma H, Kitakaze M, Sanada S et al:Carvedilol limits infarct size via adenosine-dependent mechanisms in dogs. J Am Coll Cardiol 35:350 A, 2000

• 21) Dargie HJ:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001
  pubmed

P.215 掲載の参考文献

• 1) 木之下正彦ほか:心筋梗塞二次予防に関するガイドライン.循環器病の診断と治療に関するガイドライン (1998-1999年度合同研究班報告) Jpn Circ J 65 (suppl IV):S 863-S 867, 2001

• 2) Sun Y, Weber KT:Infarct scar:a dynamic tissue. Cardiovasc Res 46:250-256, 2000
  pubmed

• 3) Yaoita H, Sakabe A, Maehara K et al:Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. Circulation 105:975-980, 2002
  pubmed

• 4) Reiken S, Wehrens XH, Vest JA et al:Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 107:2459-2466, 2003
  pubmed

• 5) Ellison KE, Hafley GE, Hickey K et al:Effect of β-blocking therapy on outcome in the multicenter unsustained tachycardia trial (MUSTT). Circulation 106:2694-2699, 2002

• 6) Sutton MJ, Lee D, Rouleau JL et al:Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation 107:2577-2582, 2003

• 7) 高野照夫ほか:急性心筋梗塞の発症状況と救急医療体制. 治療学29:529-534, 1995

• 8) Ablad B, Bjorkman JA, Gustafsson D et al:The role of sympathetic activity in atherogenesis:effects of beta-blockade. Am Heart J 116:322-327, 1988
  pubmed

P.224 掲載の参考文献

• 1) Reimer KA, Rasmussen MM, Jennings RB:On the nature of protection by propranolol against myocardial necrosis after temporary coronary occlusion in dogs. Am J Cardiol 37:520-527, 1976
  pubmed

• 2) Libby P, Maroko PR, Covell JW et al:Effect of practolol on the extent of myocardial ischaemic injury after experimental coronary occlusion and its effects of ventricular function in the normal and ischaemic heart. Cardiovasc Res 7:167-173, 1973
  pubmed

• 3) Nayler WG, Yepez CE, Fassold E et al:Prolonged protective effect of propranolol on hypoxic heart muscle. Am J Cardiol 42:217-225, 1978
  pubmed

• 4) Reimer KA, Lowe JE, Rasmussen MM et al:The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 56:786-794, 1977
  pubmed

• 5) Bush LR, Buja LM, Tilton G et al:Effects of propranolol and diltiazem alone and in combination on the recovery of left ventricular segmental function after temporary coronary occlusion and long-term reperfusion in conscious dogs. Circulation 72:413-430, 1985
  pubmed

• 6) Yusuf S, Peto R, Lewis J et al:Beta blockade during and after myocardial infarction:an overview of the randomized trials. Prog Cardiovasc Dis 27:335-371, 1985
  pubmed

• 7) The MIAMI Trial Research Group:Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J 16:199-226, 1985

• 8) The MIAMI Trial Research Group:Metoprolol in acute myocardial infarction. Enzymatic estimation of infarct size. Am J Cardiol 56:27 G-29 G, 1985

• 9) Roberts R, Croft C, Gold HK et al:Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial. N Engl J Med 311:218-225, 1984

• 10) Yusuf S, Sleight P, Rossi P et al:Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction. Circulation 67:I 32-41, 1983

• 11) Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med 310:9-15, 1984
  pubmed

• 12) Norris RM, Clarke ED, Sammel NL et al:Protective effect of propranolol in threatened myocardial infarction. Lancet ii:907-909, 1978

• 13) Han J:Mechanisms of ventricular arrhythmias associated with myocardial infarction. Am J Cardiol 24:800-813, 1969
  pubmed

• 14) Clausen T, Flatman JA:Beta 2-adrenoceptors mediate the stimulating effect of adrenaline on active electrogenic Na-K-transport in rat soleus muscle. Br J Pharmacol 68:749-755, 1980

• 15) Brown MJ, Brown DC, Murphy MB:Hypokalemia from beta 2-receptor stimulation by circulating epinephrine N Eng J Med 309:1414-1419, 1983

• 16) Norris RM, Barnaby PF, Brown MA et al:Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet ii:883-886, 1984

• 17) Rossi PR, Yusuf S, Ramsdale D et al:Reduction of ventricular arrhythmias by early intravenous atenolol in suspected acute myocardial infarction. B M J (Clin Res Ed) 286:506-510, 1983

• 18) Ryden L, Ariniego R, Arnman K et al:A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med 308:614-618, 1983
  pubmed

• 19) Evemy KL, Pentecost BL:Intravenous and oral practolol in the acute stages of myocardial infarction. Eur J Cardiol 7:391-398, 1978
  pubmed

• 20) Herlitz J, Edvardsson N, Holmberg S, et al:Goteborg Metoprolol Trial:effects on arrhythmias. Am J Cardiol 53 (suppl D):S 27-S 31, 1984

• 21) Held PH, Yusuf S:Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J 14 (suppl F):S 18-S 25, 1993

• 22) Pfeffer MA, Braunwald E:Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81:1161-1172, 1990
  pubmed

• 23) Jugdutt BI, Michorowski BL:Role of infarct expansion in rupture of the ventricular septum after acute myocardial infarction:a two-dimensional echocardiographic study. Clip Cardiol 10:641-652, 1987

• 24) Schuster EH, Bulkley BH:Expansion of transmural myocardial infarction:a pathophysiologic factor in cardiac rupture. Circulation 60:1532-1538, 1979
  pubmed

• 25) ISIS-1 (First International Study of Infarct Survival) Collaborative Group:Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction:ISIS-1. Lancet i:921-923, 1988

• 26) Anzai T, Yoshikawa T, Takahashi T et al:Early use of beta-blockers is associated with attenuation of serum C-reactive protein elevation and favorable short-term prognosis after acute myocardial infarction. Cardiology 99:47-53, 2003

• 27) Dargie HJ:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001
  pubmed

• 28) Senior R, Basu S, Kinsey C et al:Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J 137:646-652, 1999
  pubmed

• 29) Anzai T, Yoshikawa T, Shiraki H, et al.:C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 96:778-784, 1997
  pubmed

• 30) Takahashi T, Anzai T, Yoshikawa T et al:Serum C-reactive protein elevation in left ventricular remodeling after acute myocardial infarction-role of neurohormones and cytokines. Int J Cardiol 88:257-265, 2003

• 31) Maekawa Y, Anzai T, Yoshikawa T et at:Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction:a possible role for left ventricular remodeling. J Am Coll Cardiol 39:241-246, 2002

• 32) Murray DR, Prabhu SD, Chandrasekar B:Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 101:2338-2341, 2000
  pubmed

• 33) Burger A, Benicke M, Deten A et al:Catecholamines stimulate interleukin-6 synthesis in rat cardiac fibroblasts. Am J Physiol Heart Circ Physiol 281:H 14-H 21, 2001

• 34) Tsutamoto T, Wada A, Maeda K et al:Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure:prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96:509-516, 1997
  pubmed

• 35) Ohtsuka T, Hamada M, Saeki H et al:Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 89:996-999, 2002
  pubmed

• 36) Renkin J, de Bruyne B, Benit E et al:Cardiac tamponade early after thrombolysis for acute myocardial infarction:a rare but not reported hemorrhagic complication. J Am Coll Cardiol 17:280-285, 1991

• 37) Roberts R, Rogers WJ, Mueller HS et al:Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 83:422-437, 1991

• 38) Pfisterer M, Cox JL, Granger CB et al:Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction:the GUSTO-I experience. Global Utilization of Streptokinase and t-PA (alteplase) for Occluded Coronary Arteries. J Am Coll Cardiol 32:634-640, 1998

• 39) Ogawa H, Yasue H:Comparison of the effects of beta-blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese. Jpn Circ J 67:15, 2003

• 40) Ryan TJ, Antman EM, Brooks NH et al:1999 update:ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 34:890-911, 1999

• 41) Gottlieb SS, McCarter RJ, Vogel RA:Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl Med 339:489-497, 1998
  pubmed

• 42) Gheorghiade M, Goldstein S:Beta-blockers in the post-myocardial infarction patient. Circulation 106:394-398, 2002
  pubmed

P.231 掲載の参考文献

• 1) Norwegian Multicentre Group:Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304:801-807, 1981

• 2) β-Blocker Heart Attack Trial Committee:a randomized trial of propranol in patients with acute myocardial infarction, I:mortality results. JAMA 247:1707-1714, 1982

• 3) Pfeffer MA, Braunwald E, Moye LA et al:Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction:results of the survival and ventricular enlargement trial. N Engl J Med 327:669-677, 1992

• 4) Dickstein K, Kjekshus J:the OPTIMAAL steering Committee:Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction:the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360:752-760, 2002

• 5) Packer M, Bristow MR, Cohn JN et al:The effects of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355, 1996
  pubmed

• 6) Poole-Wilson PA, Swedberg K Cleland JG et al:Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET):randomized controlled trial Lancet 362:7-13, 2003

• 7) Packer M, Coats AJS, Fowler MB et al:Effect of carvedilol on survival in severe chronic heart failure N Engl Med 344:1651-1658, 2001

• 8) MERIT-HF study group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF) Lancet 353:2001-2007, 1999

• 9) CIBIS-II Investigators and Committees:The cardiac insufficiency bisoprolol study II (CIBIS II):a randomized trial Lancet 353:9-13, 1999

• 10) American heart association task force on practice guideline:1999 update ACC/AHA guidelines for the management of patients with acute myocardial infarction. www.acc.org

• 11) The CAPRICORN Investigators:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomized trial Lancet 357:1385-1390, 2001
  pubmed

• 12) Rochon PA, Tu JV, Anderson GM et al:Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction Lancet 356:639-644, 2000
  pubmed

P.238 掲載の参考文献

• 1) Heberden W:Commentaries on the history and cure of diseases In:Classics of Cardiology, Vol.1 eds by Willius FA et al, Dover Publications Inc, New York, 1941, pp.221

• 2) ISFC/WHO Task Force on standardization on clinical Nomenclature:nomenclature and criteria for diagnosis of ischemic heart disease. Circulation 59:607-609, 1979

• 3) Feldman RL:Coronary thrombosis, coronary spasm and coronary atherosclerosis and speculation on the link between unstable angina and acute myocardial infarction Am J Cardiol 59:1187-1190, 1987
  pubmed

• 4) 半田俊之介, 和井内由充子, 谷正人ほか:安定労作狭心症患者の運動耐容能規定因子-冠動脈病変と冠血流予備能. 呼と循39:917-923, 1991

• 5) Okumura K, Yasue H, Matusyama K et al:Sensitivity and specificity of intracoronary injection of acetylcholine for the induction of coronary artery spasm. J Am Coll Cardiol 12:883-888, 1988

• 6) Prinzmetal M, Ekmekei A, Kennamer R et al:Variant form of angina pectoris. JAMA 174:1794-1800, 1960

• 7) 半田俊之介, 朝倉靖:異型狭心症の疫学. 現代医療;25:1373-1381, 1993

• 8) Fuster V, Badimon L, Badimon JJ et al:The pathophysiology of cornary artery disease and the acute coronary syndrome. N Engl J Med 326:242-250, 1992;326:310-318, 1992

• 9) 半田俊之介, 青木直人:Syndrome X患者に長期的薬物治療は必要か. Modern Physician 14:1205-1209, 1994

• 10) Sigwart U, Grbic M, Payot M et al:Ischemic events during coronary artery balloon occlusion. In:Silent Myocardial Ischemia, eds by Rutishauser W et al, Springer-Verlag, Berlin, 1984, pp 29-36

• 11) Krantz DS, Hedges SM, Gabbay FH et al:Triggers of angina and ST-segment depression in ambulatory patients with coronary artery disease:evidence for an upcoupling of angina and ischemia. Am Heart J 128:703-712, 1994

• 12) Cohn PF:Silent myocardial ischemia:present status. Mod Concepts Cardiovasc Dis 56:1, 1987

• 13) Deedwania PC, Carbajal EV:Silent ischemia during daily life is an independent predictor of mortality in stable angina. Circulation 81:748-756, 1990
  pubmed

• 14) Mulcahy D, Cunningham D, Crean P et al:Circadian vairation of total ischemic burden and its alteration with anti-anginal agents. Lancet ii:755-759, 1988

• 15) Guidelines on Management of Stable Effort Angina Pectoris. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 18:394-413, 1997

• 16) 半田俊之介:狭心症治療の概要. 狭心症とβ遮断薬, 臨床薬理と臨床応用, 海老原昭夫ほか編, 中外医学社, 東京, 1989, pp.68-113

• 17) Committee on Management of Patients with Chronic Stable Angina:ACC/AHA/ACPASIM guidelines for the management of patients with chronic stable angina:executive summary and recommendations. Circulation 99:2829-2848, 1999

• 18) Committee on Management of Patients with Chronic Stable ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary artticle. Circulation 107:149-158, 2003
  pubmed

• 19) Dunselman PHJM, Kempen LHJ, Bouwens LHM et al:Value of tthe addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade. Am J Cardiol 81:128-132, 1998

• 20) Savonitto S, Ardissino D, Egstrup K et al:Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable effort angina pectoris, results of the international multicenter angina exercise (IMAGE) study. J Am Coll Cardiol 27:311-316, 1996

• 21) Emanuelsson H, Egstrup K, Nikus K et al:Antianginal efficacy of the combination of felodipine-metoprolol 10/100 mg compared with each drug alone in patients with stable effort-induced angina pectoris:a multicenter parallel group study. Am Heart J 137:854-862, 1999

• 22) Dunselman P, Liem AH, Verdel G et al:Addition of felodipine to metoprolol vs replacement of metoprolol by felodipine in patients with angina pectoris despite adequate beta-blockade, results of the felodipine ER and metoprolol CR in angina (FEMINA) study. Eur Heurt J 18:1755-1764, 1997

• 23) Armstrong PW:Stable ischemic syndromes. In:Textbook of Cardiovascular Medicine. ed by Topol EJ, Lippincott-Raven, Philadelphia, pp.333, 1998

• 24) 半田俊之介, 赤石誠:抗狭心症薬-突然死をいかに予防するか. 現代医療25:3605-3611, 1993

• 25) Gottlieb SS, McCarter RJ, Vogel RA:Effect o beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339:489-497, 1998

• 26) 半田俊之介, 椎名豊:狭心症患者における心不全の治療. 循環器NOW14狭心症, 南江堂, 東京, 1996, pp.200-204

• 27) Lahiri A, Rodrigues EA, Al-Khawaja I et al:Effects of a new vasodilating beta-blocking drug, carvedilol, on left ventricular function in stable angina pectoris. Am J Cardiol 59:769-774, 1987
  pubmed

• 28) Avezum A, Tsuyuki RT, Pogue J et al:Beta-blocker therapy for congestive heart failure:a systematic overview and critical appraisal of the published trials. Can J Cardiol 14:1045-1053, 1998

• 29) ANZ Heart Failure Research Collaborative Group:Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 349:375-380, 1997

• 30) Pennell DJ, Ray SG, Davies G et al:The carvedilol hibernation reversible ischaemia trial, marker of success (CHRISTMAS) study:methodology of a randomized, placebo controlled, multicentre study of carvedilol in hibernation and heart failure. Int J Cardiol 72:265-274, 2000
  pubmed

• 31) Cleland JGF, Pennel D, Ray S et al:The carvedilol hibernation reversible ischaemia trial:marker of success (CHRISTMAS). Eur J Heart Fail 1:191-196, 1999

• 32) Fragasso G, Chierchia SL, Pizzetti G et al:Impaired left ventricular filling dynamics in patients with angina and angiographically normal coronary arteries:effect of beta-adrenergic blockade. Heart 77:32-39, 1997
  pubmed

• 33) Braunwald E, Mark DB, Jones RH et al:Unstable angina:diagnosis and management clinical practice guideline No.10. Rockville (MD):agency for Health Care Policy and Research and the National Heart Lung and Blood Institute, Public Health Service, US Department of Health and Human Services, 1994

• 34) Gottlieb SO, Weisfeldt ML, Ouyang P et al:Effect of the addition of propranolol to therpy with nifedipine for unstabel angina:a randomized double-blind placebo-controlled trial. Circulation 73:331-337, 1986

• 35) Yusuf S, Wittes J, Friedman L:Overview of results of randomized clinical trials in heart disease. II. unstable angina, heart failure, primary prevention with aspirin and risk factor reduction. JAMA 260:2259-2263, 1988

• 36) Rizik D, Timmis GC, Grines CL et al:Immediate use of beta blockers, but not calcium blockers, improves prognosis in unstable angina. Circulation 84(suppl II):S 345, 1991 (abstr)

• 37) Lubsen J, Tijsen JGP, Kerkkamp HJJ et al:Early treatment of unstable angina in the coronary care unit:a randomized, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both:Report of the Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Br Heart J 56:400-413, 1986

• 38) Bunner M, Faber TS, Greve B et al:Usefulness of carvedilol in unstable angina pectoris. Am J Cardiol 85:1173-1178, 2000

• 39) Jonas M, Reicher-Reiss H, Boyko V et al:Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Cardiol 77:1273-1277, 1996
  pubmed

• 40) 半田俊之介, 吉川勉:β遮断薬. Medical Practice 40:587-592, 1993

• 41) Gonzalez MI:Treatment of chronic stable angina with carvedilol:a multiple-action neurohormonal antagonist. A review of controlled clinical trials. J Int Med J Res 26:107-119, 1998

P.245 掲載の参考文献

• 1) Cohn PF:Asymptomatic coronary artery disease. Pathophysiology, diagnosis, management. Mod Concepts Cardiovasc Dis 50:55-60, 1981
  pubmed

• 2) 戸嶋裕徳, 村山正博, 岸田浩ほか:本邦における無症候性心筋虚血の実態. 心臓27:87-95, 1995

• 3) 岸田浩:狭心症の発症時刻と時間治療. 無症候性心筋虚血. Prog Med 18:213-218, 1998
  Medical*Online

• 4) Pepine CJ, Kern M, Boden WE:Advisory group reports on silent myocardial ischemia, acute intervention after myocardial infarction, and postinfarction management. Review. Am J Cardiol 69:B 41-B 46, 1992

• 5) Benhorin J, Banai S, Moriel M et al:Circadian variations in ischemic threshold and their relation to the occurrence of ischemic episodes. Circulation 87:808-814, 1993

• 6) 岸田浩, 斎藤寛和:心筋虚血と日内変動. 虚血閾値と日内変動. Prog Med 18:219-224, 1998

• 7) Parker JD, Festa MA, Jimenet AH et al:Morning increase in ambulatory ischemia in patients with stable coronary artery disease. Importance of physical activity and increased cardiac demand. Circulation 89:604-614, 1994

• 8) Stone PH, Gibson RS, Glasser SP et al:Comparison of propranolol, diltiazem, and nifedipine in the stable angina. Different effects on ambulatory ischemia, exercise performance, and anginal symptoms. Circulation 82:1962-1972, 1990

• 9) Frishman WH, Glasser S, Stone P et al:Comparison of controlled-onset, extended release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol 83:507-514, 1999
  pubmed

• 10) Davies RF, Habibi H, Klinke WP et al:Effects of amlodine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. J Am Coll Cardiol 25:619-625, 1995

• 11) Borer JS, Fox K, Jaillon P et al:Antianginal and antiischemic effects of ivabradine, an I (f) inhibitor, in stable angina. A randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107:817-823, 2003

• 12) Huikuri HV, Niemela MJ, Ojala S et al:Circadian rhythms of frequency domain measures of heart rate variability in healthy subjects and patients coronary artery disease. Effects of arousal and upright posture. Circulation 90:121-126, 1994
  pubmed

• 13) Pepine CJ, Cohn PF, Deedwania PC et al:Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 90:762-768, 1994
  pubmed

• 14) Aronow WS, Ahn C, Mercando AD et al:Decrease in mortality by propranolol in patients with heart disease and complex ventricular arrhythmias is more an anti-ischemic than antiarrhythmic effect. Am J Cardiol 74:613-615, 1994
  pubmed

• 15) Glamann DB, Lange RA, Hillis LD:Beneficial effect of long-term beta blockade after acute myocardial infarction in patients without antegrade flow in the infarct artery. Am J Cardiol 68:150-154, 1991

Part 7/ 不整脈治療薬としてのβ遮断薬

P.253 掲載の参考文献

• 1) Echt DS, Liebson PR, Mitchell LB et al:Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781 788, 1991

• 2) β-Blocker Heart Attack Trial Group:A randomized trial propranolol in patients with acute myocardial infarction. Mortality results. JAMA 247:1707-1714, 1982

• 3) The MIAMI trial research group:Metoprolol in acute myocardial infarction (MIAMI). A randomized placebo-controlled international trial. Eur Heart J 6:199-226, 1985

• 4) CIBIS-II Investigators and Committees:The cardiac insufficiency bisoprolol study II (CIBIS-II):a randomized trial. Lancet 353:9-13, 1999

• 5) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999

• 6) Packer M, Bristow MR, Cohn JN et al:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355, 1996
  pubmed

• 7) Opie LH:Receptors and signal transduction. In:The Heart:Physiology, from Cell to Circulation, ed by Opie LH, Lippincott Williams & Wilkins, Philadelphia, 1998, pp.173-207

• 8) Rockman HA, Koch WJ, Lefkowitz RJ:Seven-transmembrane-spanning receptors and heart function. Nature 415:206-212, 2002
  pubmed

• 9) Wallukat G:The β-adrenergic receptors. Herz 27:683-690, 2002

• 10) Yazawa K, Kameyama M:Mechanism of receptor-mediated modulation of the delayed outward potassium current in guinea-pig ventricular myocytes. J Physiol 421:135-150, 1990
  pubmed

• 11) Bahinski A, Nairn AC, Greengard P et al:Chloride conductance regulated by cyclic AMP-dependent protein kinase in cardiac myocytes. Nature 340:718-721, 1989
  pubmed

• 12) DiFrancesco D:The onset and autonomic regulation of cardiac pacemaker activity:relevance of the f current. Cardiovasc Res 29:449-456, 1998

• 13) Xiao RP, Cheng H, Zhou YY et al:Recent advances in cardiac β 2-adrenergic signal transduction. Circ Res 85:1092-1100, 1999

• 14) Singh BN, Sarma JSM:Beta-blockers and calcium channel blockers as antiarrhythmic drugs. In:Cardiac Electrophysiology from Cell to Bedside, ed by Zipes DP, WB Saunders, Philadelphia, PA, 1999, pp.903-921

• 15) Huycke EC, Lai WT, Nguyen NX, et al:Role of intravenous isoproterenol in the electrophysiologic induction of atrial ventricular nodal reentrant tachycardia in patients with dual atrial ventricular nodal pathway. Am J Cardiol 64:1131-1137, 1989

• 16) Kuppersmith J:Cellular mechanism of antiarrhythmic action of beta blocker. In:Beta-Blockers and Cardiac Arrhythmias, ed by Deddwania PC, Marcel Dekkar, New York, 1992, pp.1-33

• 17) Kowey PR, Taylor JE, Rials SJ, et al:Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery by-pass grafting. Am J Cardiol 69:963-965, 1992

• 18) Venkatesh N, Padbury JF, Singh BN:Effects of amiodarone and desethylamiodarone on rabbit myocardial beta-adrenoceptors and serum thyroid hormones--absence of relationship to serum and myocardial drug concentrations. J Cardiovasc Pharmacol 8:989-997, 1986
  pubmed

• 19) Anderson JL, Prystowsky EN:Sotalol. An important new antiarrhythmic. Am J Cardiol 137:388-409, 1999

• 20) Haissaguerre M, Jais P, Shah DC et al:Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339:659-666, 1998
  pubmed

• 21) Chen SA, Hsieh MH, Tai CT et al:Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins. Electro-physiological characteristics, pharmacological responses, and effects of radio-frequency ablation. Circulation 100:1879-1886, 1999

• 22) Schauerte P, Scherlag BJ, Patterson E et al:Focal atrial fibrillation:experimental evidence for a pathophysiologic role of the autonomic nervous system. J Cardiovasc Electrophysiol 12:592-599, 2001
  pubmed

• 23) Honjo H, Boyett MR, Niwa R et al:Pacing-induced spontaneous activity in myocardial sleeves of pulmonary veins after treatment with ryanodine. Circulation 107:1937-1943, 2003
  pubmed

• 24) Inoue H, Zipes DP:Results of sympathetic denervation in the canine heart:supersensitivity that may be arrhythmogenic. Circulation 75:877-887, 1987
  pubmed

• 25) Vasallo JA, Cassidy DM, Kindwall KE et al:Nonuniform recovery of excitability in the left ventricle. Circulation 78:1365-1372, 1988

• 26) Glancy JM, Garratt CJ, Woods KL et al:QT dispersion and mortality after myocardial infarction. Lancet 345:945-948, 1995
  pubmed

• 27) Fesmire SI, Marcoux LG, Lyyski DS et al:Effect of selective versus nonselective beta blockade on QT dispersion in patients with nonischemic dilated cardiomyopathy. Am J Cardiol 84;350-354, 1999
  pubmed

• 28) Day CP, McComb JM, Campbell RWF:QT dispersion. An indication of arrhythmia risk in patients with long QT intervals. Br Heart J 63:342-344, 1990

• 29) Yildirir A, Sade E, Tokgozoglu L et al:The effects of chronic carvedilol therapy on QT dispersion in patients with congestive heart failure. Eur J Heart Fail 3:717-721, 2001

• 30) Roukema G, Singh JP, Maijs M et al:Effect of exercise-induced ischemia on QT interval dispersion. Am Heart J 135:88-92, 1998

• 31) Pogwizd SM, Schlotthauer K, Li L et al:Arrhythmogenesis and contractile dysfunction in heart failure. Roles of sodium-calcium exchange, inward rectifier potassium current, and residual β-adrenergic responsiveness. Cir Res 88:1159-1167, 2001

• 32) Marks AR:Cardiac intracellular calcium release channels. Role in heart failure. Circ J Res 87:8-11, 2000

• 33) Reiken S, Gaburjakova M, Gaburjakova J et al:β-adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure. Circulation 104:2843-2848, 2001

• 34) Laitinen PJ, Brown KM, Piippo K et al:Mutations of the cardiac ryanodine receptor (RyR 2) gene in familial polymorphic ventricular tachycardia. Circulation 103:485-490, 2001

• 35) Wehrens XHT, Lehnart SE, Huang F et al:FKBP 12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 113:829-840, 2003

• 36) Sun ZH, Swan H, Viitasalo M et al:Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome. J Am Coll Cardiol 31:1400-1405, 1998
  pubmed

• 37) Weiss JN, Garfinkel A, Karagueuzian HS et al:Chaos and the transition to ventricular fibrillation:a new approach to antiarrhythmic drug evaluation. Circulation 99:2819-2826, 1999
  pubmed

• 38) Qu Z, Weiss JN, Garfinkel A:Cardiac electrical restitution properties and stability of reentrant spiral waves:a simulation study. Am J Physiol 276:H 269-H 283, 1999.

• 39) Garfinkel A, Kim YH, Voroshilovsky et al:Preventing ventricular fibrillation by flattening cardiac restitution. Proc Natl Acad Sci 97:6061-6066, 2000
  pubmed

• 40) Taggart P, Sutton P, Chalabi Z et al:Effect of adrenergic stimulation on action potential duration restitution in humans. Circulation 107:285-289, 2003
  pubmed

P.260 掲載の参考文献

• 1) Fuster V, Ryden LE, Asinger RW et al:ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation:Executive summary. Circulation 104:2118-2150, 2001
  pubmed

• 2) Wyse DG, Waldo AL, DiMarco JP et al:The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Inverstigators:A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825-1833, 2002

• 3) Van Gelder IC, Hagens VE, Bosker HA et al:the Rate Control Versus Electrical Cardiovesion for Persistent Atrial Fibrillation Study Group:A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Eng J Med 347:1834-1840, 2002

• 4) 心房細動治療(薬物) ガイドライン. Jpn Circ J Med (suppl V):S 931-S 998, 2001

• 5) Teo KK, Yusuf S, Furberg CD:Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 270:1589-1595, 1993
  pubmed

• 6) Yusuf S, Peto R, Lewis J et al:Beta blockade during and after myocardial infarction:an overview of the randomized trials. Prog Cardiovasc Dis 27:335-371, 1985
  pubmed

• 7) Yusuf S, Wittes J, Friedman L:Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 260:2088-2093, 1988
  pubmed

• 8) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353:2001-2007, 1999

• 9) CIBIS-II Study Group:The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II):a randomised trial. Lancet 353:9-13, 1999

• 10) Leizorovicz A, Lechat P, Cucherat M et al:Bisoprolol for the treatment of chronic heart failure:a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J 143:301-307, 2002
  pubmed

• 11) Packer M, Bristow MR, Cohn JN et al:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group. N Engl J Med 334:1349-1355, 1996

• 12) Maggioni AP:Heart Failure:treatment strategies for heart failure:β blockers and antiarrhythmics. Heart 85:97-103, 2001

Part 8/ 心不全治療薬としてのβ遮断薬

P.270 掲載の参考文献

• 1) Colucci WS, Packer M, Bristow MR et al:the US Carvedilol Heart Failure Study Group:Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 94:2800-2806, 1996

• 2) MERIT-HF-Study group:Effect of metoprolol CR/XL in chronic heart failure:metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001-2007, 1999

• 3) CIBIS II Investigators and Committees:The cardiac insufficiency bisoprolol study II (CIBOS II):a randomised trial. Lancet 353:9-13, 1999

• 4) Packer M, Coats AJS, Fowler MB et al:the Carvedilol Prospective Randomized Cumulative Survival Study Group:Effect of carvedilol on survival in severe chronic heart failure. N Eng J Med 344:1651-1658, 2001

• 5) The CAPRICORN Investigators:Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction:the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001
  pubmed

• 6) LeJemtel TH, Galveo M, Sonnenblick EH:Beta-adrenergic blockade reverses, while ACE inhibition attenuates, left ventricular remodeling in patients with chronic heart failure. Heart Failure 14:57-63, 1998

• 7) Eichhorn EJ, Bedotto JB, Malloy CR et al:Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvement in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 24:1310-1320, 1990

• 8) Bristow MR, Gilbert EM:Improvement in cardiac myocyte function by biological effects of medical therapy:a new concept in the treatment of heart failure. Eur Heart J 16 (suppl F):S 20-S 31, 1995

• 9) Eichhorn EJ, Bristow MR:Medical therapy can improve the biological properties of the chronically failing heart:a new era in the treatment of heart failure. Circulation 94:2285-2296, 1996

• 10) Eichhorn EJ:Restoring function in failing hearts:the effects of beta blockers. Am J Med 104:163-169, 1998
  pubmed

• 11) Anderson JL, Gilbert EM, O'Connell JB et al:Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 17:1373-1381, 1991
  pubmed

• 12) Hall SA, Cigarroa CG, Marcoux L et al:Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 25:1154-1161, 1995
  pubmed

• 13) Andersson B, Caidahl K, di Lenarda A et al:Changes in early and late diastolic filling patterns induced by long-term adrenergic beta-blockade in patients with idiopathic dilated cardiomyopathy. Circulation 94:673-682, 1996
  pubmed

• 14) Doughty RN, Whalley GA, Gamble G et al:Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 29:1060-1066, 1997
  pubmed

• 15) Lowes BD, Gill EA, Abraham WT et al:Effects of carvedilol on left venticular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 83:1201-1205, 1999

• 16) Groenning BA, Nilsson JC, Sondergaad L et al:Antiadrenergic effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 36:2072-2080, 2000

• 17) Naqvi TZ, Goel RK, Forrester JS:Usefulness of left ventricular mass in predicting recovery of left ventricular systolic function in patients with symptomatic idiopathic dilated cardiomyopathy. Am J Cardiol 85:624-629, 2000
  pubmed

• 18) Capomolla S, Febo O, Gnemmi M et al:Beta-blockade therapy in chronic heart failure:diastolic function and mitral regurgitation improvement by carvedilol. Am Heart J 139:696-708, 2000

• 19) Bristow MR:Mechanism and clinical rationales for using beta-blockers in heart failure. J Card Fail 6 (suppl I):S 8-S 14, 2000

• 20) Bristow MR:Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 80 (11A):L 26-L 40, 1997

• 21) Sharpe N, Smith H, Murphy J et al:Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin converting enzyme inhibitor. Lancet 337:872-876, 1991
  pubmed

• 22) Konstam MA, Rousseau MF, Kronenberg MW et al:the SOLVD Investigators:Effects of the angiotensin converting enzyme inhibitor enalapril on the long term progression of the left ventricular dysfunction in patients with heart failure. Circulation 86:431-438, 1992

• 23) Greenberg B, Quinones MA, Kolipillai C et al:the SOLVD Investigators:Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography study. Circulation 91:2573-2581, 1995

• 24) Francis GS, Cohn JN, Jhonson G et al:V-HeFT VA Cooperative Study Group:Plasma norepinephrine, plasma renin activity, and congestive heart failure. Circulation 87 (suppl VI):S 40-S 48, 1993

• 25) Cohn J, Levine T, Oliveri M et al:Plasma norepinephrine as a guide to prognosis in patients with chronic heart failure. N Engl J Med 311:819-823, 1984

• 26) Hasking GJ, Esler MD, Jennings GL et al:Norepinephrine spillover to plasma in patients with congestive heart failure:evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 73:913-919, 1986

• 27) Leimbach WN, Wallin GB, Victor RG et al:Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 73:913-919, 1986

• 28) Kaye DM, Lambert GW, Lefkovits J et al:Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 23:570-578, 1994
  pubmed

• 29) Grassi G, Sevalle G, Cattaneo BM et al:Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 92:3206-3211, 1995

• 30) Rundqvist B, Elam M, Sverrisdottir Y et al:Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation 95:169-175, 1997

• 31) Bristow MR, Minobe W, Rasmussen R et al:β-Adrenergic neuroeffector abnormality in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest 89:803-815, 1992

• 32) Bengel FM, Permanetter B, Ungerer M et al:Relationship between altered sympathetic innervation, oxidative metabolism and contractile function in the cardiomyopathic human heart. Eur Heart J 22:1594-1600, 2001
  pubmed

• 33) Kaye DM, Lefkovits J, Jennings GL et al:Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 26:1257-1263, 1995

• 34) Bristow MR:Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 80 (11A):L 26-L 49, 1997

• 35) Colucci WS, Sawyer DB, Singh K et al:Adrenergic overload and apoptosis in heart failure:implications for therapy. J Card Fail 6:1-7, 2000
  pubmed

• 36) Mann DL, Kent RL, Parsons B et al:Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 85:790-804, 1992
  pubmed

• 37) Bahmbi B, Eghbali M:Effects of norepinephrine on myocardial collagen gene expression and response of cardiac fibrosis after norepinephrine treatment. Am J Pathol 139:1131-1142, 1991

• 38) Linck B, Boknik P, Baba HA etal:Long-term beta adrenoceptor mediated alteration in contractility and expression of phospholamban and sarcoplasmic reticulum Ca-ATPase in mammalian ventricle. J Pharmacol Exp Ther 286:531-538, 1998
  pubmed

• 39) Boluyt MO, Long X, Eschenhagen T et al:Isoproterenol infusion induces alteration in expression of hypertrophy-associated genes in rat heart. Am J Physiol 269:H 638-H 647, 1995

• 40) Remondino A, Kwon SH, Communal C et al:β-Adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen specific/c-Jun NH2-terminal kinase-dependent activation of the mito-chondrial pathway. Circ Res 92:136-138, 2003

• 41) Marks SO, Reiken S, Hisamatsu Y et al:PKA phosphorylation dissociates FKBP 12.6 from the calcium release channel (ryanodine receptor):defective regulation in failing hearts. Cell 101:365-376, 2000

• 42) Marks AR:Cardiac intracellular calcium release channels:role in heart failure:Circ Res 87:8-11, 2000
  pubmed

• 43) Iwase B, Bishop SP, Uechi M et al:Adverse Effects of chronic endogenous sympathetic drive induced by cardiac Gs overexpression. Circ Res 78:517-524, 1996

• 44) Hori M, Ssto H, Iwai K et al:Norepinephrine disrupt cytoskeletal framework of microtubules in rat hearts. Jpn Circ J 56:462-468, 1992

• 45) Hori M, Sato H, Iwai K et al:Disruption of microtubles in cultured neonatal rat cardiomyocytes during rapid contractions:protective effects of beta-adrenoceptor antagonist. Jpn Circ J 56:62-68, 1992

• 46) Senzaki H, Paolocci P, Gluzband YA et al:β-Blockade prevents sustained metallo-proteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction. Cir Res 86:807-815, 2000

• 47) Hasenfuss G, Rinecke H, Struder R et al:Relation between myocardial function and expression of sarcoplasmic reticulum Ca ATPase in failing and nonfailing human myocardium. Circ Res 75:434-432, 1994

• 48) de Tombe PP:Altered contractile function in heart failure. Cardiovasc Res 37:367-380, 1998
  pubmed

• 49) Pieske B, Maier LD, Bers DM et al:Ca handling and sarcoplasmic reticulum Ca content in isolated failing and nonfailing human myocardium. Circ Res 85:38-46, 1999

• 50) Ito K, Yan X, Tajima M et al:Contractile reserve and intracellular calcium regulation in mouse myocyte from normal and hypertrophied hearts. Circ Res 87:588-595, 2000
  pubmed

• 51) Hobai IA, O'Rourke B:Decreased sarcoplasmic reticulum calcium content is responsible for defective excitation-contractile coupling in canine heart failure. Circulation 103:1577-1584, 2001
  pubmed

• 52) Kubo H, Margulies KB, Piacentio III V et al:Patients with end-stage congestive heart failure treated with β-adrenergic antagonists have improved ventricular myocyte calcium regulatory protein abundance. Circulation 104:1012-1018, 2001

• 53) Lowes BD, Gilbert EM, Abraham WT et al:Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346:1357-1365, 2002
  pubmed

• 54) Reiken S, Wehrens XHT, Vest JA et al:β-Blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 107:2459-2466, 2003

• 55) Eicchorn EJ:Prognosis determination in heart failure. Am J Med 110(7 A):S 14-S 36, 2001

• 56) Bristow MR, Gilbert EM, Abraham WT et al:the MOCHA Investigators:Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94:2807-2816, 1996
  pubmed

• 57) Swedberg K, Bristow MR, Cohn JN et al:Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 105:1797-1803, 2002
  pubmed

• 58) CIBIS II Investigators and Committees:The Cardiac Insufficiency Bisoprolol Study II (CIBIS II):a randomised trial. Lancet 353:9-13, 1999

• 59) Basu S, Senior R, Raval U et al:Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction:a placebo-controlled, randomized trial. Circulation 96:183-191, 1997
  pubmed

• 60) CIBIS Investigators and Committee:A randomised trial of beta-blockade in heart failure:the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 90:1765-1773, 1994
  pubmed

• 61) Cleland JGF, Pennell DJ, Ray SG et al:CHRISTMAS Investigators:Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial):randomised controlled trial. Lancet 362:14-21, 2003
  pubmed

• 62) Metra M, Giubbini R, Nadari S et al:Differential effects of-blockers in patients with heart failure:a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 102:546-551, 2000

• 63) Tsutamoto T, Hisanaga T, Wada A et al:Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 31:391-398, 1998
  pubmed

• 64) Ohtsuka T, Hamada M, Saeki H et al:Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 89:996-999, 2002
  pubmed

• 65) Pool-Wilson PA, Swedberg K, Cleland JGF et al:Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET):randomised controlled trial. Lancet 362:7-13, 2003

• 66) Bristow MR:What type of beta blocker should be used to treat chronic heart failure? Circulation 102:484-486, 2000
  pubmed

• 67) Bohler S, Saubadu S, Scheldewaert R et al:Betaxolol versus carvedilol in chronic heart failure (BETACAR study). Arzneimittelforschung 49:311-317, 1999
  pubmed

• 68) Waagstein F, Bristow MR, Swedberg K et al:Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342:1141-1446, 1993

• 69) Keith M, Geranmayegan A, Sole MJ et al:Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 31:1352-1356, 1998
  pubmed

• 70) Ide T, Tsutsui H, Kinugawa S et al:Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 85:357-363, 1999
  pubmed

• 71) Hare JM, Stamler JS:NOS:modulator, not mediator of cardiac performance. Nat Med 5:273-274, 1999
  pubmed

• 72) Saavedra WF, Paolocci N, St John ME et al:Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 90:297-304, 2002
  pubmed

• 73) Heymes C, Bendall JK, Ratajczak P et al:Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41:2164-2171, 2003
  pubmed

• 74) Heineke J, KempfT, Kraft T et al:Downregulation of cytoskeletal muscle LIM protein by nitric oxide. Impact on cardiac myocyte hypertrophy. Circulation 107:1424-1432, 2003
  pubmed

• 75) Flesch M, Maak C, Cremers B et al:Effects of β-blockers on free radical-induced cardiac contractile dysfunction. Circulation 100:346-353, 1999

• 76) Ruffolo RR, Feuerstein GZ:Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovasc Pharmacol 32(suppl 1):S 22-S 29, 1998

• 77) Mak S, Newton GE:The oxidative stress hypothesis of congestive heart failure. Radical thoughts. Chest 120:2035-2046, 2001
  pubmed

• 78) Feuerstein GZ, Yue T, Ma X et al:Novel mechanism in the treatment of heart failure:Inhibition of oxygen radical and apoptosis by carvedilol. Prog Cardiovasc Dis 41(suppl 1):S 17-S 24, 1998

• 79) Ruffolo RR, Feuerstein GZ:Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovasc Pharmacol 32(suppl 1):S 22-S 30, 1998

• 80) Arumanayagam M, Chan S, Tong S et al:Antioxidant properties of carvedilol and metoprolol in heart failure:a double-blind randomized controlled trial. J Cardiovasc Pharmacol 37:48-54, 2001

• 81) Nakamura K, Kusano K, Nakamura Y et al:Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 105:2867-2871, 2002
  pubmed

• 82) Kukin ML, Kalman J, Charney RH et al:Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 99:2645-2651, 1991
  pubmed

• 83) Paolisso G, Gambardella A, Galzerano De et al:Total body and myocardial substrate oxidation in congestive heart failure. Metabolism 43:174-179, 1994

• 84) Lommi J, Kupari M, Yki-Jarvinen H:Free fatty acid kinetics and oxidation in congestive heart failure. Am J Cardiol 81:45-50, 1998
  pubmed

• 85) Taylor M, Wallhaus TR, DeGrado TR et al:An evaluation of myocardial fatty acid and glucose uptake using PET with [18F] fluolo-6-thoa-heptadecanoic acid and [18F] FDG in patients with congestive heart failure. J Nucl Med 42:55-62, 2001

• 86) Hasenfuss G, Maier LS, Hermann HP et al:Influence of pyruvate on contractile performance and Ca2+cycling in isolated failing human myocardium. Circulation 105:194-199, 2002
  pubmed

• 87) Sack MN, Rader TA, Park S et al:Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94:2837-2842, 1996
  pubmed

• 88) Recchia FA, McConnell PI, Bernstein RD et al:Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacinginduced heart failure in the conscious dog. Circ Res 83:969-979, 1998
  pubmed

• 89) Eichhorn EJ, Heesch CM, Barnett JH et al:Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy. A randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 24:1310-1320, 1994
  pubmed

• 90) Wallhaus TR, Taylor M, DeGrado TR et al:Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 103:2441-2446, 2001
  pubmed

• 91) Paolisso G, Gambardella A, Marrazzo G et al:Metabolic and cardiovascular benefits deriving from β-adrenergic blockade in chronic congestive heart failure. Am Heart J 123:123-110, 1992

• 92) Panchal AR, Stanley WC, Kerner J et al:Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure. J Card Fail 4:121-126, 1998
  pubmed

• 93) Ishida Y, Yasumura Y, Fukuchi K et al:β-Blocker therapy reduces glucose-dependency of myocardial energy metabolism in patients with idiopathic dilated cardiomyopathy:estimation by a post-heparine F-18 FDG PET study. Circulation 106 (suppl II):S478, 2002

• 94) Woodley SL, Gilbert EM, Anderson JL et al:β-Blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 84:2426-2296, 1991

• 95) McNamara DM, Holubkov R, Janosko K et al:Pharmaclogenic interactions between β-blocker therapy and the angiotensin-converting enzyme deletion polymorphysm in patients with congestive heart failure. Circulation 103:1644-1648, 2001

• 96) Magnusson Y, Hoebeke J, Waagstein F et al:Predictive role of β1-autoantibodies in patients with idiopathic dilated cardiomyopathy treated with metoprolol. Circulation 90:1543, 1994

• 97) Brede M, Wiesmann F, Jahns R et al:Feedback inhibition of cathecolamine release by two different α 2-adrenoceptor subtypes prevents progression of heart failure. Circulation 106:2491-2496, 2002

• 98) Small KM, Wagoner LE, Levine AM et al:Synergic polymorphism of β1-and α 2 C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 15:1135-1142, 2002

• 99) Delahaye F, de Gevigney G:Is the optimal dose of angiotensin converting enzyme inhibitors in patients with congestive heart failure definitely established? J Am Coll Cardiol 36:2069-2097, 2000

• 100) Campbell DJ, Aggarwal A, Esler M et al:β-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet 358:1609-1610, 2001

• 101) Emanueli C, Maestri R, Corradi D et al:Dilated and failing cardiomyopathy in brady-kinin B 2 receptor knockout mice. Circulation 100:2359-2365, 1999

• 102) Cleland JGF, Witte K, Thackray S:Bradykinin and ventricular function. Eur Heart J 2 (suppl H):S 20-S 29, 2000

• 103) Packer M, Poole-Wilson A, Armstrong PW et al:the ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 100:2312-2318, 1999

• 104) Packer M, Colucci WS, Sackner-Bernstein JD et al:the PRECISE Sudy Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial. Circulation 94:2793-2799, 1996

• 105) Cohn JN, Toggnoni G et al:the Varsartan Heart Failure Trial Investigators:A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667-1675, 2001

• 106) Granger CB, McMurray JJV, Yusuf S et al:the CHARM investigators and committees:Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors:the CHARM-Alternative trial. Lancet 362:772-776, 2003
  pubmed

• 107) McMurray JJV, Ostergren J, Swedberg K et al:the CHARM investigators and committees:Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors:the CHARM-Added trial. Lancet 362:767-771, 2003
  pubmed

• 108) Struthers AD:Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 16 (suppl N):S103-S 106, 1995

• 109) Weber KT. Aldosterone in congestive heart failure:N Engl J Med 345:1689-1697, 2001
  pubmed

• 110) Pitt B, Zannad F, Remme WJ et al:the Randomized Aldactone Evaluation Study Investigators:The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709-717, 1999
  pubmed

• 111) Negut C:Effects of beta-blocker therapy in severe chronic heart failure. N Engl J Med 345:998, 2001
  pubmed

• 112) Bauersachs J, Fraccarollo D, Ertl G et al:Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition. Mechanistic evidence to support RALES. Circulation 102:2325-2328, 2000
  pubmed

• 113) Yoshikawa T, Baba A, Suzuki M et al:Effectiveness of carvedilol alone versus carvedilol+pimobendan for severe congestive heart failure. Am J Cardiol 85:1495-1497, 2000
  pubmed

• 114) Shakar SF, Abraham WT, Gilbert EM et al:Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failue. J Am Coll Cardiol 31:1336-1340, 1998

• 115) Bristow MR, Shakar SS, Linseman JV et al:Inotropes and β-blocker:Is there a need for new guidelines? J Card Fail 7(suppl 1):S8-S12, 2001

• 116) Takemura K, Yasumura Y, Hirooka K et al:Low-dose amiodarone for patients with advenced heart failure who are intolerant of beta-blockers. Jpn Circ J 66:441-444, 2002

P.281 掲載の参考文献

• 1) Levy D, Garrison RJ, Savage DD et al:Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561-1565, 1990
  pubmed

• 2) 甲斐久史, 今泉勉:心室リモデリングと心不全. 心不全フロンティア, 小室一成 編, メディカルレビュー社, 大阪, 2003, pp.75-83

• 3) Verdecchia P, Schillaci G, Borgioni C et al:Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97:48-54, 1998
  pubmed

• 4) Dahlof B, Pennert K, Hansson L:Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 5:95-110, 1992
  pubmed

• 5) Cruickshank JM, Lewis J, Moore V et al:Reversal of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 6:85-90, 1992
  pubmed

• 6) Schmieder RE, Schlaich MP, Klingbeil AU et al:Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 275:1507-1513, 1996

• 7) Dahlof B, Devereux RB, Kjeldsen SE et al:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomized trial against atenolol. Lancet 359:995-1003, 2002
  pubmed

• 8) Dahlof B, Zanchetti A, Diez J et al:Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertension. J Hypertens 20:1855-1864, 2002
  pubmed

P.287 掲載の参考文献

• 1) CIBIS Investigators and Committee:A randomized trial of β-blockade in heart failure:the cardiac insufficiency bisoprolol study (CIBIS). Circulation 90:1765-1773, 1994

• 2) CIBIS-II Investigators and Committee:The cardiac insufficiency bisoprolol study II (CIBIS-II):A randomized trial. Lancet 353:9-13, 1999

• 3) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomized Investigation Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999

• 4) Packer M, Colucci WS, Sackner-Bernstein JD et al:Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 94:2793-2799, 1996
  pubmed

• 5) Packer M, Coats AJS, Fowler MB et al:Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001

• 6) Cohn JN, Levine TB, Olivari MT et al:Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819-823, 1984
  pubmed

• 7) Bristow MR:beta-adrenergic receptor blockade in chronic heart failure. Circulation 101:558-569, 2000
  pubmed

• 8) Rockman HA, Chien KR, Choi DJ et al:Expression of a beta-adrenergic receptor kinase inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci USA.95:7000-7005, 1998

• 9) Schmidt U, Hajjar RJ, Kim CS et al:Human heart failure:camp stimutaion of SR Ca2+-ATPase activity and phosphorylation level of phospholamban. Am J Physiol 277 (2 Pt 2):H474-H480, 1999

• 10) Yano M, Kobayashi S, Kohno M et al:FKBP 12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation 107:477-484, 2003

• 11) Kubo H, Margulies KB, Piacentino III V et al:Patients with end-stage congestive heart failure treated with β-adrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance. Circulation 104:1012-1018, 2001

• 12) Judith K, Catherine S, Roger J et al:Cellular and molecular remodeling in a heart failure model treated with the β-blocker carteolol. Am J Physiol 276:1678-1690, 1999

• 13) Yano M, Ono K, Ohkusa T et al:Altered stoichiometry of FKBP 12.6 versus ryanodine receptor as a cause of abnormal Ca2+ leak through ryanodine receptor in heart failure. Circulation 102:2131-2136, 2000

• 14) Marx SO, Reiken S, Hisamatsu Y et al:PKA phosphorylation dissociates FKBP 12.6 from the calcium release channel (ryanodine receptor):defective regulation in failing hearts. Cell 101:365-376, 2000

• 15) Reiken S, Gaburjakova M, Gaburjakova J et al:β-Adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure. Circulation 104:2843-2848, 2001

• 16) Reiken S, Wehrens XH, Vest JA et al:Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 107:2459-2466, 2003
  pubmed

• 17) Doi M, Yano M, Kobayashi S et al:Propranolol prevents the development of heart failure by restoring FKBP 12.6-mediated stabilization of ryanodine receptor. Circulation 105:1374-1379, 2002

P.293 掲載の参考文献

• 1) Andreka P, Aiyar N, Olson LC et al:Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 105:2429-2434, 2002
  pubmed

• 2) Maack C, Bohm M, Vlaskin L et al:Partial agonist of bucindolol is dependent on the activation state of the human β1-adrenergic receptor. Circulation 108:348-353, 2003

• 3) Metra M, Giubbini R, Nodari S et al:Differential effects of beta-blockdrs in patients with heart failure. Circulation 102:546-551, 2000
  pubmed

• 4) Poole-Wilson PA, Swedberg K, Cleland J et al:Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET). Lancet 362:7-13, 2003

• 5) Exner DV, Dries DL, Waclawiw MA et al:Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction. J Am Coll Cardiol 33:916-923, 1999
  pubmed

• 6) The CHRISTMUS Investigators:Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMUS trial). Lancet 362:14-21, 2003

P.299 掲載の参考文献

• 1) Kannel WB, Belanger AJ:Epidemiology of heart failure. Am Heart J 121:951-957, 1991
  pubmed

• 2) Hunt SA, Baker DW, Chin MH et al:ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. J Am Coll Cardiol 38:2101-2113, 2001
  pubmed

• 3) 日本循環器学会:慢性心不全治療ガイドライン. Jpn Circ J 64 (suppl IV):S1023-S 1079, 2000

• 4) Tsuchihashi M, Tsutsui H, Kodama K et al:Clinical characteristics and prognosis of hospitalized patients with congestive heart failure--a study in Fukuoka, Japan. Jpn Circ J 64:953-959, 2000
  pubmed

• 5) Tsutsui H, Tsuchihashi M, Takeshita A:Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol 88:530-533, 2001
  pubmed

• 6) Tsuchihashi M, Tsutsui H, Kodama K et al:Medical and socioenvironmental predictors of hospital readmission in patients with congestive heart failure. Am Heart J 142:E 7, 2001

• 7) Packer M, Bristow MR, Cohn JN et al:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334:1349-1355, 1996

• 8) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999

• 9) CIBIS-II Study Group:The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II):a randomised trial. Lancet 353:9-13, 1999

• 10) Packer M, Coats AJ, Fowler MB et al:Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001
  pubmed

• 11) Smith GL, Masoudi FA, Vaccarino V et al:Outcomes in heart failure patients with preserved ejection fraction:mortality, readmission, and functional decline. J Am Coll Cardiol 41:1510-1518, 2003

• 12) Soumerai SB, McLaughlin TJ, Spiegelman D et al:Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 277:115-121, 1997
  pubmed

• 13) Rochon PA, Tu JV, Anderson GM et al:Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction. Lancet 356:639-644, 2000
  pubmed

• 14) Poole-Wilson PA, Swedberg K, Cleland JG et al:Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET):randomised controlled trial. Lancet 362:7-13, 2003

• 15) Rich MW, Beckham V, Wittenberg C et al:A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 333:1190-1195, 1995
  pubmed

P.305 掲載の参考文献

• 1) Stevenson WG, Sweeney MO:Arrhythmias and sudden death in heart failure. Jpn Circ J 61:727-740, 1997
  pubmed

• 2) Koseki Y, Watanabe J, Shinozaki T et al:The CHART Investigators:Characteristics and 1-year prognosis of medically treated patients with chronic heart failure in Japan. Circ J 67:431-436, 2003
  pubmed

• 3) 循環器病の診断と治療に関するガイドライン (1999-2000年度合同研究班報告). Jpn Circ J 65 (suppl):V, 2001

• 4) Buxton AE, Fisher JD, Josephson ME et al:Prevention of sudden death in patients with coronary artery disease:the Multicenter Unsustained Tachycardia Trial (MUSTT). Prog Cardiovasc Dis 36:215 226, 1993

• 5) Moss AJ, Zareba W, Hall WJ et al:Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877-883, 2002
  pubmed

• 6) Packer M, Bristow MR, Cohn JN et al:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334:1349-1355, 1996

• 7) Bristow MR, Gilbert EM, Abraham WT et al:Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 94:2807-2816, 1996
  pubmed

• 8) Australia/New Zealand Heart Failure Research Collaborative Group:Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 349:375-380, 1997

• 9) Packer M, Coats AJ, Fowler MB et al:Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001

• 10) CIBIS-II Investigators and Committees:The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II):a randomised trial. Lancet 353:9-13, 1999

• 11) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999

• 12) Dargie HJ:The CAPRICORN Investigators:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001
  pubmed

• 13) Beta-Blocker Evaluation of Survival Trial Investigators:A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344:1659-1667, 2001

• 14) Davies MK:Xamoterol and the failing heart. Lancet 335:117-118, 1990
  pubmed

• 15) Poole-Wilson PA, Swedberg K, Cleland JGF et al:Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET):randomised controlled trial. Lancet 362:7-12, 2003

• 16) Lechat P, Hulot JS, Escolano S et al:Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 103:1428-1433, 2001
  pubmed

• 17) Joglar JA, Acusta AP, Shusterman NH et al:Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction:retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 142:498-501, 2001
  pubmed

• 18) Hunt SA, Baker DW, Chin MH et al:ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult:executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 38:2101-2113, 2001

P.313 掲載の参考文献

• 1) Senni M, Tribouilloy CM, Rodeheffer RJ et al:Congestive heart failure in the community:a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 98:2282-2289, 1998
  pubmed

• 2) Vasan RS, Larson MG, Benjamin EJ et al:Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction. J Am Coll Cardiol 33:1948 1955, 1999

• 3) Galldhi SK, Powers JC, Nomeir AM et al:The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 344:17-22, 2001

• 4) Ennezat PV, Emezat CA, Malendowicz S et al:From systolic to diastolic chronic heart failure (Abst). J Am Coll Cardiol 35 (suppl A):S163, 2000

• 5) Doi R, Masuyama T, Yamamoto K et al:Development of different phenotypes of hypertensive heart failure:systolic versus diastolic failure in Dahl salt-sensitive rats. J Hypertens 18:111-120, 2000
  pubmed

• 6) Sakata Y, Masuyama T, Yamamoto K et al:Calcineurin inhibitor attenuates left ventricular hypertrophy leading to prevention of heart failure in hypertensive rats. Circulation 102:2269-2275, 2000
  pubmed

• 7) Sakata Y, Masuyama T, Yamamoto K et al:Renin angiotensin system-dependent hypertrophy as a contributor to heart failure in hypertellsive rats:different characteristics from renin angiotensin system-independent hypertrophy. J Am Coll Cardiol 37:293-299, 2001
  pubmed

• 8) Yamamoto K, Masuyama T, Sakata Y et al:Prevention of diastolic heart failure by endothelin type A receptor antagonist through inhibition of ventricular structural remodeling in hypertensive heart. J Hypertens 20:753-761, 2002

• 9) Sakata Y, Yamamoto K, Mano T et al:Angiotensin II type 1 receptor blockade prevents diastolic heart failure through inodulation of Ca2+regulatory proteins and extracellular matrix. J Hypertens 21:1737-1745, 2003

• 10) Yamamoto K, Masuyama T, Sakata Y et al:Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 55:76-82, 2002

• 11) Yamamoto K, Redfield MM, Nishimura RA:Analysis of left ventricular diastolic function. Heart 75 (suppl 2):S27-S 35, 1996

• 12) Masuyama T, Popp RL:Doppler evaluation of left ventricular filling in congestive heart failure. Eur Heart J 18:1548-1556, 1997
  pubmed

• 13) Redfield MM, Jacobsen SJ, Burnett JC Jr et al:Burden of systolic and diastolic ventricular dysfunction in the community:appreciating the scope of the heart failure epidemic. JAMA 289:194-202, 2003
  pubmed

• 14) Zile MR, Gaasch WH, Carroll JD et al:Heart failure with a normal ejection fraction:is measurement of diastolic fullction necessary to make the diagnosis of diastolic heart failure? Circulation 104:779-7882, 2001
  pubmed

• 15) Yamaguchi H, Yoshida J, Yamamoto K et al:Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol, 2004 (in press)

• 16) Chen HH, Lainchbury JG, Senni M et al:Diastolic heart failure in the community:clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. J Card Fail 8:279-287, 2002
  pubmed

• 17) Doi M, Yano M, Kobayashi S et al:Propranolol prevents the development of heart failure by restoring FKBP 12.6-mediated stabilization of ryanodine receptor. Circulation 105:1374-1379, 2002

• 18) Plank DM, Yatani A, Ritsu H et al:Calcium dynamics in the failing heart:restoration by beta-adrenergic receptor blockade. Am J Physiol 285:H305-H 315, 2003

• 19) Prabhu SD, Chandrasekar B, Murray DR et al:Beta-adrenergic blockade in developing heart failure:effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 101:2103-2109, 2000
  pubmed

• 20) Nakamura K, Kusano K, Nakamura Y et al:Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 105:2867-2871, 2002
  pubmed

• 21) Yusuf S, Pfeffer MA, Swedberg K et al:Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction:the CHARM-Preserved Trial. Lancet 362:777-781, 2003
  pubmed

P.320 掲載の参考文献

• 1) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036, 1975
  pubmed

• 2) Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999
  pubmed

• 3) CIBIS II Investigators and Committees:The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II):a randomised trial. Lancet 353:9-13, 1999

• 4) Packer M, Coats AJ, Fowler MB et al:Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001
  pubmed

• 5) Hunt SA, Baker DW, Chin MH et al:ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult. Circulation 104:2996-3007, 2001
  pubmed

• 6) EPOCH study:Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure:the effects of pimobendan on chronic heart failure study. Circ J 66:149-157, 2002
  pubmed

• 7) MUCHA試験:第4回日本心不全学会総会 2000年10月 MUCHA Investigator group

• 8) ARCH試験:第65回日本循環器学会総会 2001年3月(松森昭先生発表)

• 9) Bristow MR, Gilbert EM, Abraham WT et al:Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 94:2807-2816, 1996
  pubmed

• 10) Packer M, Fowler MB, Roecker EB et al:Effect of carvedilol on the morbidity of patients with severe chronic heart failure:results of the Carvedilol Prospective Randomized Cumulative Survival (COPER-NICUS) Study. Circulation 106:2194-2199, 2002

• 11) Lowes BD, Gilbert EM, Abraham WT et al:Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346:1357-1365, 2002
  pubmed

• 12) Borjesson M, Magnusson Y, Hjalmarson A et al:A novel polymorphism in the gene coding for the beta (1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 21:1853-1858, 2000
  pubmed

• 13) Small KM, Wagoner LE, Levin AM et al:Synergistic polymorophsms of beta 1 and alpha 2 c-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347:1135-1142, 2002

• 14) Brodde OE, Buscher R, Tellkamp R et al:Blunted cardiac responses to receptor activation in subjects with Thr 164 Ile beta(2)-adrenoceptors. Circulation 103:1048-1050, 2001

• 15) Huang J, Chuang SK, Cheng CL et al:Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. Clin Pharmacol Ther 65:402-407, 1999
  pubmed

• 16) Johnson JA, Burlew BS:Metoprolol metabolism via cytochrome P450 2D 6 in ethnic populations. Drug Metab Dispos 24:350-355, 1996

Part 9/ 心血管手術とβ遮断薬

P.329 掲載の参考文献

• 1) Allaf DE, D'Orio V, Carlier J:The New inotropic phosphodiesterase inhibitors. Arch Int Physiol Biochem 92:69-79, 1984

• 2) Weber KT, Gill SK, Janicki JS et al:Newer positive inotropic agents in the treatment of chronic cardiac failure. Drugs 33:503-519, 1987
  pubmed

• 3) Dage RC, Roebel LE, Hsieh CP et al:Cardiovascular properties of a new cardiotonic agent:MDL 17,043. J Cardiovasc Pharmacol 4:500-519, 1988

• 4) Bethke T, Eschenhagen T, Klimkiewicz A et al:Phosphodiesterase inhibition by enoximone in preparations from nonfailing and failing human hearts. Arzneimittelforschung 42:437-445, 1992
  pubmed

• 5) Francis GS:Development of arrhythmias in the patient with congestive heart failure:pathophysiology, prevalence and prognosis. Am J Cardiol 57:B3-B7, 1986

• 6) Packer M, Bristow MR, Cohn JN et al for the US Carvedilol Heart Failure Study Group:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Eng J Med 334:1349-1355, 1996

• 7) Batista RJV, Santos JLV, Takeshita N:partial left ventriculectomy to improve left ventricular function in end-stage heart disease. J Cardiac Surg 11:96-97, 1996

• 8) Dor V, Sabatier M, DiDonato M et al:Efficacy of endoventricular patch plasty in large postinfarction akinetic scar and severe left ventricular dysfunction:comparison with a series of large dyskinetic scars. J Thorac Cardiovasc Surg 116:50-59, 1998

• 9) Katz AM:Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation 73 (suppl III):S184-S 188, 1986

• 10) Almassi GH, Schowalter T, Nicolosi AC et al:Atrial fibrillation after cardiac surgery:A Major Morbid Event? Ann Surg 226:501-511, 1997

• 11) Hogue C, Hyder M:Atrial fibrillation after cardiac operation:risks, mechanisms, and treatment. Ann Thorac Surg 69:300-306, 2000
  pubmed

• 12) Zaman AG, Archbold RA, Helft G et al:Atrial fibrillation after coronary bypass surgery. A model for preoperative risk stratification. Circulation 101:1403-1406, 2000

• 13) Jideus L, Blomstrom P, Nilsson L et al:Tachyarrhythmias and triggerring factors for atrial fibrillation after coronary artery bypass operations. Ann Thorac Surg 69:1064-1069, 2000

• 14) Maisel WH, Rawn JD, Stevenson WG:Atrial fibrillation after cardiac surgery. Ann Intern Med 135:1061-1073, 2001
  pubmed

• 15) Creswell LL, Schuessler RB, Rosenbloom M et al:Hazards of postoperative atrial arrhythmias. Ann Thorc Surg 60:1709-1715, 1995

• 16) Gavaghan TP, Feneley MP, Campbell TJ et al:Atrial tachyarrhythmias after cardiac surgery:results of disopyramide therapy. Aust NZ J Med 15:27-32, 1985

• 17) Asher CR, Miller DP, Grimm RA et al:Analysis of risk factor for development of atrial fibrillation early after cardiac valvular surgery. Am J Cardiol 82:892-895, 1998
  pubmed

• 18) Mendes LA, Connelly GP, McKenney PA et al:Right coronary stenosis:an independent predictor of atrial fibrillation after coronary artery bypass surgery. J Am Coll Cardiol 25:198-202, 1995
  pubmed

• 19) ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery:Executive summary and recommendation. Circulation 100:1464-1480, 1999
  pubmed

• 20) Ryan TJ, Antman EM, Brooks NH et al:1999 update:ACC/AHA Guidelines for the management of patients with acute myocardial infarction:executive summary and recommendations:a report of the ACC/AHA task for on practice guidelines (committee on management of acute myocardial infarction). Circulation 100:1016-1030, 1999
  pubmed

• 21) Basu S, Senior R, Raval U et al:Beneficial effects of intravenous and oral carvedilol treatment in acute randomized infarction. Circulation 96:183-191, 1997
  pubmed

• 22) Gottlieb SS, McCarter RJ, Vogel RA:Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339:489-497, 1998
  pubmed

• 23) Committee on Management of Patients With Chronic Stable Angina:ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina:executive summary and recommendations. Circulation 99;2829-2848, 1999
  pubmed

• 24) ANZ Heart Failure Research Collaborative Group:Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 34:375-380, 1997

• 25) Andrews TC, Reimold SC, Berlin JA et al:Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta-analysis of randomized control trials. Circulation 84 (suppl 5):III 236-III 244, 1991

• 26) Maisel WH, Rawn JD Stevenson WG:Atrial fibrillation after cardiac surgery. Ann Intern Med 135:1061-1073, 2001
  pubmed

• 27) Ferguson TB Jr, Coombs LP, Peterson ED:Society of Thoracic Surgeons National Adult Cardiac Surgery Database:Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America. JAMA 287:2221-2227, 2002
  pubmed

• 28) Janssen J, Loomans L, Harink J et al:Prevention and treatment of supraventricular tachycardia shortly after coronary artery bypass grafting:a randomized open trial. Angiology 37:601-609, 1986
  pubmed

• 29) Suttorp MJ, Kingma JH, Gin MTJ et al:Efficacy and safely of low-and high-dose sotalol versus propranolol in the prevention of supraventricular tachyarrhythmias early after coronary artery bypass operations. J Thorac Cardiovasc Surg 100:921-926, 1990

• 30) Farshi R, Kistner D, Sarma JS et al:Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise:a crossover open-label study of five drug regimens. J Am Coll Cardiol 33:304-310, 1999
  pubmed

• 31) Duport A:Effects of carvedilol on renal function. Eur J Clin Pharmacol 38 (suppl 2):S96-S 100, 1990

• 32) Morady F:Prevention of atrial fibrillation in the postoperative cardiac patient. significance of oral class III antiarrhythmic agents. Am J Cadiol 84 (suppl 9 A):S156-S 160, 1999

• 33) Senior R, Muller-Beckmann B, DasGupta P et al:Effects of Carvedilol on Veritricular Arrhythmias. J Cardiol Pharmacol 19(suppl I):S117-S 121, 1992

• 34) Perterson FD, Brown AM:Pressor reflexes produced by stimulation of afferent fibers in the cardiac sympathetic nerves of the cat. Circ Res 28:605-610, 1971

• 35) Prys-Roberts C:Anesthesia and hypertention. Br J Anaesth 56:711 721, 1984

• 36) Abbroud FM:The sympathetic system in hypertension. State of the art review. Hypertension 4:208-225, 1982

• 37) Richards DA, Tukman J, Prichard BNC:Assessment of alpha adrenoceptor blocking actions of labetalol. Br J Clin Pharmacol 3:849-855, 1976

• 38) Brogden RN, Heel RC, Speight TM et al:Labetalol:a review of its pharmacology and therapeutic use in hypertension. Drugs 15:251-270, 1978
  pubmed

• 39) Mehta J, Cohn JN:Haemodynamic effects of labetalol, an alpha and bata adrenergic blocking agent in hypertensive subjects. Circulation 55:370-375, 1977

• 40) Gold ML, Sacks DJ, Grosnoff DB et al:Use of during anesthesia to treat tachycardia and hypertension. Anesth Analg 68:101-104, 1989

• 41) Gray RJ, Beteman TM, Czer LS et al:Use of esmolol in hypertension after cardiac surgery. Am J Cardiol 56 (suppl F):S49-S 56, 1985

• 42) Harrison L, Ralley FE et al:The role of an ultra short-acting adrenergic blocker (esmolol) in patients undergoing coronary artery bypass surgery. Anesthesiology 66:413-418, 1987
  pubmed

• 43) Sung JS, Blamski L, Kirshenbaum J et al:Esmolol Research Group. Clinical experience with esmolol, short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia. J Clin Pharmacol 26 (suppl A):S15-S26, 1986

• 44) Reilly CS, Wood M, Koshakji RP et al:Ultra-short acting beta-blockade:a comparison with conventional blockade. Clin Pharmacol Ther 38:579-585, 1985
  pubmed

• 45) Cooley DA, Hency WS, Amad KH et al:Ventricular aneurysm following myocardial infarction. Results of surgical treatment. Am Surg 150:595, 1959

• 46) Dor V, Sabatier M, Coste P et al:Left ventricular aneurysm. A new surgical approach. Thoracic Cardiovascular Surgery 37:11-19, 1995

• 47) McCarthy PM, Young JB, Starling RC et al:Anterior infarct exclusion surgery for ischemic cardiomyopathy. Circulation 100 (Suppl I):S514, 1999

• 48) McCarthy PM, Bishay EB, Hoercher KJ et al:Mitral valve surgery for cardiomyopathy:late outcomes and effect on rehospitalizations for congestive heart failure. Circulation 100:1-514 (abstr 2709), 1999

• 49) 川名正敏:心不全治療の進歩と重症心不全に対する複合治療戦略. Cardiovascular Med-Surg 2:9-14, 2000
  Medical*Online

• 50) Radack K, Deck C:β-Adrenergic blocker therapy dose not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 151:1769-1776, 1991

• 51) Shores J, Berger KR, Murphy EA et al:Progression of aortic dilatation and benefit of long-term β-adrenergic blockade in Marfan's syndrome. N Engl J Med 330:1335-1341, 1994

• 52) Olsen SL, Gilbert EM, Renlund DG et al:Carvedilol improves left ventricular function and symptoms in chronic heart failure:a double-blind randomized study. J Am Coll Cardiol 25:1225-1231, 1995
  pubmed

Part 10/ β遮断薬使用上の注意点

P.338 掲載の参考文献

• 1) 清水昭彦, 松崎益徳:β遮断薬の上手な使い方と副作用.循環科学17:1106-1109, 1997

• 2) 宇佐美等:β遮断薬の副作用と対処法.小児内科25:345-349, 1993

• 3) Shanes JG:β-Blockade rational or irrational therapy for congestive heart failure? Circulation 76:971-973, 1987

• 4) Packer M, Bristow MR, Cohn J et al:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355, 1996
  pubmed

• 5) Kostis JB, Rosen RC:Central nervous system effects of β-adrenergic blocking drugs:the role of ancillary properties. Circulation 75:204-212, 1987

• 6) Rodger JC, Sheldon CD, Lerski RA et al:Intermittent claudication complicating beta-blockade. BMJ 1:1125, 1976
  pubmed

• 7) Manttari M, Tenkanen L, Manninen V et al:Antihypertensive therapy in dyslipidemic men. Effects on coronary heart disease incident and total mortality. Hypertension 25:47-52, 1995
  pubmed

• 8) Ebstein M, Oster JR:Beta-blocker and the kidney. Mineral Electrolyte Metab 8:237-254, 1995

• 9) Kohno M, Murakawa K, Okamura M et al:Effects of long-term administration of carvedilol on renal haemodynamics and functions in DOCA salt-induced accelerated hypertension of spontaneously hypertensive rats. Drugs 36 (suppl 6):S165-S 168, 1988

• 10) Vincent HH, Man in't Veld AJ, Boomsma F et al:Prevention of epinephrine-induced hypokalemia by non selected beta blockers. Am J Cardiol 56 (suppl D):S10-S 14, 1985

• 11) Cottrill CM, McAllister RG Jr, Gettes L et al:Propranolol therapy during pregnancy, labor and delivery:evidence for transplacental drug transfer and impaired neonatal drug disposition. J Pediatr 91:812-814, 1977
  pubmed

• 12) Haraldsson A, Geven W:Severe adverse effects of maternal labetalol in a premature infant. Acta Pediatr Scand 78:956-958, 1989

• 13) Schmimmel MA, Eidelman AJ, Wilschanski MA et al:Toxic effects of atenolol consumed during breast feeding. J Pediatr 114:476-478, 1989

• 14) Skegg DCG, Doll R:Frequency of eye complaints and rashes among patients receiving practolol and propranolol. Lancet ii:475-478, 1977

• 15) Marshall AJ, Baddeley H, Barritt DW et al:Practolol peritonitis. Q J Med 46:135-149, 1977
  pubmed

• 16) Harty RF:Sclerosing peritonitis and propranolol. Arch Intern Med 138:1424-1426, 1978
  pubmed

P.344 掲載の参考文献

• 1) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036, 1975
  pubmed

• 2) Waagstein F, Bristow MR, Swedberg K et al:Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 342:1441-1446, 1993

• 3) Packer M, Bristow MR, Cohn JN et al:The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure. N Engl J Med 334:1349-1355, 1996
  pubmed

• 4) CIBIS-II investigators and Committee:The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II):a randomized trial. Lancet 353:9-13, 1999

• 5) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001 2007, 1999

• 6) Handa S, Ilosoda S, Sasayama S et al:Multicenter Carvedilol Heart Failure Assessment Trial (MUCHA). J Cardiac Failure 6 (suppl 3):S81, 2000

• 7) Weir MR, Moser M:Diuretics and beta-blockers:is there a risk for dyslipidemia? Am Heart J 139:174-183, 2000

• 8) Messerli FH, Grossman E, Goldbourt U:Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? JAMA 279:1903-1907, 1999

• 9) Grossman E, Messerli FH.:Why beta-blockers are not cardioprotective in elderly patients with hypertension. Curr Cardiol Rep 4:468-473, 2002

• 10) 日和田邦男, 荻原俊男:厚生労働省研究班「老年者の高血圧治療ガイドライン2002改訂版」. 日老医会誌39:322-351, 2002

P.350 掲載の参考文献

• 1) Silver JM, Yudofsky SC, Kogan M et al:Elevation of thioridazine plasma levels by propranolol. Am J Psychiat 143:1290-1292, 1986
  pubmed

• 2) Greendyke RM, Gulya A:Effect of pindolol administration on serum levels of thioridazine, haloperidol, phenytoin, and phenobarbital. J Clin Psychiatry 49:105-107, 1988
  pubmed

• 3) Zaman R, Kendall MJ, Biggs PI:The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide. Br J Clin Pharmacol 13:507-512, 1982
  pubmed

• 4) Massara F, Strumia E, Camanni F et al:Depressed tolbutamide-induced insulin response in subjects treated with propranolol. Diabetologia 7:287-289, 1971
  pubmed

• 5) Sagie A, Strasberg B, Kusnieck J et al:Symptomatic bradycardia induced by the combination of oral diltiazem and beta blockers. Clin Cardiol 14:314-316, 1991
  pubmed

• 6) Bailey RR, Neale TJ:Rapid clonidine withdrawal with blood pressure overshoot exaggerated by beta-blockade. BMJ 1:942-943, 1976
  pubmed

• 7) Cumming AD, Robertson C:Interaction between disopyramide and practolol. BMJ 2:1264, 1979
  pubmed

• 8) Rynne MV:Timolol toxicity:ophthalmic medication complicating systemic disease. Case reports. J Maine Med Ass 71:82, 1980
  pubmed

• 9) Durao V, Prata MM, Goncalves LM:Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis. Lancet 2:1005-1007, 1977
  pubmed

• 10) Kirch W, Spahn H, Kohler H et al:Accumulation and adverse effects of metoprolol and propranolol after concurrent administration of cimetidine. Arch Toxicol 6 (suppl 1):S379-S383, 1983

• 11) Herman RJ, Nakamura K, Wilkinson GR et al:Induction of propranolol metabolism by rifampicin. Br J Clin Pharmacol 16:565-569, 1983
  pubmed

Part 11/ 基礎編

P.358 掲載の参考文献

• 1) Ahlquist RP:Astudy of the adrenotropic receptors. Am J Physiol 153:586-600, 1948

• 2) Lands AM, Arnold A, McAuliff JP et al:Differentiation of receptor systems activated by sympathomimetic amines. Nature 214:597-598, 1967
  pubmed

• 3) Black JW, Stephenson JS:Pharmacology of a new adrenergic beta-receptor-blocking compound (Nethalide). Lancet ii:311-314, 1962

• 4) Dixon RA, Kobilka BK, Strader DJ et al:Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature 321:75-79, 1986
  pubmed

• 5) Kobilka BK, Dixon RA, Frielle T et al:cDNA for the human beta 2-adrenergic receptor:a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci USA 84:46-50, 1987
  pubmed

• 6) Frielle T, Collins S, Daniel KW et al:Cloning of the cDNA for the human beta 1-adrenergic receptor. Proc Natk Acad Sci USA 84:7920-7924, 1987

• 7) Emorine LJ, Marullo S, Briend-Sutren MM et al:Molecular characterization of the human beta 3-adrenergic receptor. Science 245:1118-1121, 1989
  pubmed

• 8) Steinberg SF:The molecular basis for distinct beta-adrenergic receptor subtype actions in cardiomyocytes. Circ Res 85:1101-1111, 1999
  pubmed

• 9) Gauthier C, Leblais V, Kobzik L at al:The negative inotropic effect of beta 3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 102:1377-1384, 1998

• 10) Granneman JG:The putative beta 4-adrenergic receptor is a novel state of the beta 1-adrenergic receptor. Am J Physiol Endocrinol Metab 280:E199-E 202, 2001

• 11) Castellano M, Bohm M:The cardiac beta-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease. Hypertension 29:715-722, 1997
  pubmed

• 12) Gether U, Asmar F, Meinild AK et al:Structural basis for activation of G-protein-coupled receptors. Pharmacol Toxicol 91:304-312, 2002
  pubmed

• 13) Strader CD, Fong TM, Tota MR et al:Structure and function of G protein-coupled receptors. Annu Rev Biochem 63:101-132, 1994
  pubmed

• 14) Tota MR, Candelore MR, Dixon RA et al:Biophysical and genetic analysis of the ligand-binding site of the beta-adrenoceptor. Trends Pharmacol Sci 12:4-6, 1991
  pubmed

• 15) Hoffman BB, Lefkowitz RJ:Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. McGraw-Hill, New York, 1996, pp.199-248

• 16) Ruffolo RR Jr, Feuerstein GZ, Ohlstein EH:Recent observations with beta-adrenoceptor blockade. Beneficial effects in hypertension and heart failure. Am J Hypertens 11 (1 Pt 2):S9-S 14, 1998

• 17) Ishikawa Y, Homcy CJ:The adenylyl cyclases as integrators of transmembrane signal transduction. Circ Res 80:297-304, 1997
  pubmed

• 18) Kotlikoff MI, Kamm KE:Molecular mechanisms of beta-adrenergic relaxation of airway smooth muscle. Annu Rev Physiol 58:115-141, 1996
  pubmed

• 19) Wong SK:G protein selectivity is regulated by multiple intracellular regions of GPCRs. Neurosignals 12:1-12, 2003
  pubmed

• 20) Xiao RP, Cheng H, Zhou YY et al:Recent advances in cardiac beta (2)-adrenergic signal transduction. Circ Res 85:1092-1100, 1999
  pubmed

• 21) 1watsubo K, Tsunematsu T, Ishikawa Y:Isoform-specific regulation of adenylyl cyclase:a potential target in future pharmacotherapy. Expert Opin Ther Targets 7:441-451, 2003

• 22) Lai NC, Roth DM, Gao MH et al:Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricular function and cAMP-generating capacity. Circulation 102:2396-2401, 2000
  pubmed

• 23) Okumura S, Kawabe J, Yatani A et al:Type 5 adenylyl cyclase disruption alters not only sympathetic but also parasympathetic and calcium-mediated cardiac regulation. Circ Res 93:364-371, 2003

• 24) Okumura S, Takagi G, Kawabe J et al:Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci USA 100:9986-9990, 2003
  pubmed

• 25) Claing A, Laporte SA, Caron MG et al:Endocytosis of G protein-coupled receptors:roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol 66:61-79, 2002
  pubmed

• 26) Blaxall BC, Pellett AC, Wu SC et al:Purification and characterization of beta-adrenergic receptor mRNA-binding proteins. J Biol Chem 275:4290-4297, 2000
  pubmed

• 27) Schlegel A, Pestell RG, Lisanti MP:Caveolins in cholesterol trafficking and signal transduction:implications for human disease. Front Biosci 5:D929-D 937, 2000

• 28) Steinberg SF, Brunton LL:Compartmentation of G protein-coupled signaling pathways in cardiac myocytes. Annu Rev Pharmacol Toxicol 41:751-773, 2001
  pubmed

• 29) Rohrer DK, Desai KH, Jasper JR et al:Targeted disruption of the mouse beta 1-adrenergic receptor gene:developmental and cardiovascular effects. Proc Natl Acad Sci USA 93:7375-7380, 1996
  pubmed

• 30) Rohrer DK, Schauble EH, Desai KH et al:Alterations in dynamic heart rate control in the beta 1-adrenergic receptor knockout mouse. Am J Physiol 274:H1184-H 1193, 1998

• 31) Chruscinski AJ, Rohrer DK, Schauble E et al:Targeted disruption of the beta 2 adrenergic receptor gene. J Biol Chem 274:16694-16700, 1999

• 32) Rohrer DK, Chruscinski A, Schauble EH et al:Cardiovascular and metabolic alterations in mice lacking both beta l-and beta 2-adrenergic receptors. J Biol Chem 274:16701-16708, 1999

• 33) Singh K, Xiao L, Remondino A et al:Adrenergic regulation of cardiac myocyte apoptosis. J Cell Physiol 189:257-265, 2001
  pubmed

• 34) Jurevicius J, Fischmeister R:cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by beta-adrenergic agonists. Proc Natl Acad Sci 93:295-299, 1996
  pubmed